[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 323
1. Wang XY, Wang M, Ma XY: Bis(mu-benzene-1,2-dicarboxylato)bis{aqua[2-(2-chloro-6-fluorophenyl)-1H-imidazo[4,5-f][1,10]phenanthroline]cadmium(II)} and its zinc(II) analogue. Acta Crystallogr C; 2009 Dec;65(Pt 12):m459-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the isomorphous title compounds, [Cd(2)(C(8)H(4)O(4))(2)(C(19)H(10)ClFN(4))(2)(H(2)O)(2)] and [Zn(2)(C(8)H(4)O(4))(2)(C(19)H(10)ClFN(4))(2)(H(2)O)(2)], the Cd(II) centre is seven-coordinated by two N atoms from one [2-(2-chloro-6-fluorophenyl)-1H-imidazo[4,5-f][1,10]phenanthroline (L) ligand, one water O atom and four carboxylate O atoms from two different benzene-1,2-dicarboxylate (1,2-bdc) ligands in a distorted pentagonal-bipyramidal coordination, while the Zn(II) centre is six-coordinated by two N atoms from one L ligand, one water O atom and three carboxylate O atoms from two different 1,2-bdc ligands in a distorted octahedral coordination.
  • Each pair of adjacent metal centres is bridged by two 1,2-bdc ligands to form a dimeric structure.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966426.001).
  • [ISSN] 1600-5759
  • [Journal-full-title] Acta crystallographica. Section C, Crystal structure communications
  • [ISO-abbreviation] Acta Crystallogr C
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


2. Németh I, Sükösd F, Béli L, Kiss A, Pajor L, Mikó T, Iványi B: [Adult renal neoplasms in the material of the Pathology Department of the Szeged University]. Orv Hetil; 2005 Apr 3;146(14):653-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult renal neoplasms in the material of the Pathology Department of the Szeged University].
  • AIMS: The authors investigated the frequencies of the various histological types of adult renal tumours.
  • Among the malignant tumours, the frequency of renal cell carcinomas was 91.1% (n = 371).
  • 88.4% of the renal cell carcinomas (n = 328) were of conventional type, 5.6% (n = 21) were papillary and 4% (n = 15) were chromophobe.
  • The authors observed 3 Bellini duct, 1 mucinous tubular and 3 non-classifiable carcinomas, with a combined incidence of 1.8%.
  • 84.5% of the conventional carcinomas were clear cell (n = 277), 8.8% were eosinophilic granular (n = 29), 3.9% were multilocular cystic (n = 13) and 2.7% were sarcomatoid carcinomas (n = 9).
  • The median age of the patients with conventional carcinoma was 60 (median, range: 25-84), in the papillary group it was 62 (43-78), and in the chromophobe group was 59 (17-77).
  • The median age of patients affected by transitional cell carcinoma was 64 (range: 45-81).
  • CONCLUSIONS: Adult malignant renal tumours affect mainly patients around the age of 60.
  • The commonest diagnosis was clear cell carcinoma of conventional type.
  • The incidence of clear cell carcinoma was 5% higher than that reported in the literature (84.5% vs 70-80%) whereas that of papillary carcinoma was 5% lower (5% vs 10-15%).
  • In comparison with the literature data, oncocytomas were relatively common (8% instead of 3%), and not rarely, it was difficult to distinguish them from renal cell carcinomas.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / pathology. Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / epidemiology. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / epidemiology. Adenoma, Oxyphilic / pathology. Adult. Aged. Angiomyolipoma / epidemiology. Angiomyolipoma / pathology. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / pathology. Female. Humans. Hungary / epidemiology. Male. Middle Aged. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889540.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


3. Tsai WC, Sheu LF, Nieh S, Yu CP, Sun GH, Lin YF, Chen A, Jin JS: Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol; 2007 Mar;25(1):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters.
  • We tested the hypothesis that expression of EMMPRIN and fascin correlate with clinicopathological parameters of renal cell carcinoma (RCC).
  • Immunohistochemical analysis of EMMPRIN and fascin were performed in tissue microarrays of 100 surgical specimens, including 35 clear-cell RCC (CRCC), 21 clear-cell RCC with granular differentiation (GRCC), 12 chromophobe RCC (ChRCC), 8 papillary RCC (PRCC), 9 carcinoma of the collecting duct of Bellini (CDC), 10 clear-cell RCC with sarcomatoid differentiation (SRCC), and 6 metastatic RCC.
  • [MeSH-major] Antigens, CD147 / metabolism. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carrier Proteins / metabolism. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Microfilament Proteins / metabolism

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Res. 2003 Apr;1(6):420-7 [12692261.001]
  • [Cites] Ann Diagn Pathol. 2005 Dec;9(6):307-11 [16308158.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2730-4 [7708715.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):357-66 [15017593.001]
  • [Cites] Pathol Int. 2006 Jul;56(7):359-67 [16792544.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):994-6 [9307206.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):888-91 [10706100.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):590-6 [15363811.001]
  • [Cites] Urol Int. 2001;67(2):130-4 [11490206.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):494-504 [7960219.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):434-9 [7812975.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6335S-41S [15448027.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] J Cell Sci. 1994 Feb;107 ( Pt 2):477-86 [8207074.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):699-704 [1701851.001]
  • [Cites] Thromb Haemost. 2005 Feb;93(2):199-204 [15711733.001]
  • [Cites] Trends Cardiovasc Med. 2004 Aug;14(6):221-6 [15451513.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 [9293916.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1800-10 [16721788.001]
  • [Cites] Int J Urol. 2006 May;13(5):573-80 [16771728.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • (PMID = 17021824.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 136894-56-9 / Antigens, CD147; 146808-54-0 / fascin
  •  go-up   go-down


Advertisement
4. Hawxwell SM, Adams H, Brammer L: Two-dimensional metal-organic frameworks containing linear dicarboxylates. Acta Crystallogr B; 2006 Oct;62(Pt 5):808-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Zn(BDC)(DMF) [(1) where BDC = benzene-1,4-dicarboxylic acid; DMF = N,N-dimethylformamide] adopts a common paddlewheel motif leading to a 4(4) grid network, whereas Zn(3)(BDC)(3)(EtOH)(2) (2), Zn(3)(BDC)(3)(H(2)O)(2) * 4DMF (3) and Zn(3)(BPDC)(3)(DMF)(2) * 4DMF (4) each form networks with the relatively uncommon 3(6) topology based upon Zn(3)(O(2)CR)(6) secondary building units.
  • Comparison of structures (2) and (3) illustrates a clay-like flexibility in interplanar spacing which sheds light on the ability of the Zn(3)(BDC)(3) framework to undergo desolvation and uptake of small solvent and gas molecules.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16983162.001).
  • [ISSN] 0108-7681
  • [Journal-full-title] Acta crystallographica. Section B, Structural science
  • [ISO-abbreviation] Acta Crystallogr., B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


5. Cot SS, So AK, Espie GS: A multiprotein bicarbonate dehydration complex essential to carboxysome function in cyanobacteria. J Bacteriol; 2008 Feb;190(3):936-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using biochemical activity assays and molecular approaches we have identified a catalytic, multiprotein HCO3- dehydration complex (BDC) associated with the protein shell of Synechocystis carboxysomes.
  • The complex was minimally composed of a CcmM73 trimer, CcaA dimer, and CcmN.
  • Yeast two-hybrid analyses indicated that the BDC was associated with the carboxysome shell through CcmM73-specific protein interactions with CcmK and CcmL.
  • The specificity of the CcmM73-CcaA interaction provided both a mechanism to integrate CcaA into the fabric of the carboxysome shell and a means to recruit this enzyme to the BDC during carboxysome biogenesis.
  • Functionally, CcaA was the catalytic core of the BDC.
  • CcmM73 bound H14CO3- but was unable to catalyze HCO3- dehydration, suggesting that it may potentially regulate BDC activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D237-40 [17135202.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18368-73 [17116880.001]
  • [Cites] Methods Enzymol. 1972;25:579-84 [23014442.001]
  • [Cites] J Mol Biol. 2007 Sep 21;372(3):764-73 [17669419.001]
  • [Cites] Planta. 2002 Jan;214(3):456-67 [11859847.001]
  • [Cites] J Exp Bot. 2003 Feb;54(383):609-22 [12554704.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3381-5 [12824332.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16107-12 [14673118.001]
  • [Cites] J Bacteriol. 2004 Feb;186(3):623-30 [14729686.001]
  • [Cites] Protein Eng Des Sel. 2004 Mar;17(3):285-91 [15051865.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W590-4 [15215457.001]
  • [Cites] Methods Enzymol. 1982;87:732-52 [6294458.001]
  • [Cites] J Bacteriol. 1989 Nov;171(11):6069-76 [2509426.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4437-41 [1584776.001]
  • [Cites] J Bacteriol. 1993 May;175(10):2871-9 [8491708.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6909-13 [8041719.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2323-30 [8665839.001]
  • [Cites] DNA Res. 1996 Jun 30;3(3):109-36 [8905231.001]
  • [Cites] Plant Mol Biol. 1998 May;37(2):205-15 [9617794.001]
  • [Cites] Annu Rev Plant Biol. 2005;56:99-131 [15862091.001]
  • [Cites] Science. 2005 Aug 5;309(5736):936-8 [16081736.001]
  • [Cites] J Exp Bot. 2006;57(2):249-65 [16216846.001]
  • [Cites] J Mol Biol. 2000 Jun 2;299(2):499-520 [10860755.001]
  • [Cites] Biochemistry. 2000 Aug 8;39(31):9222-31 [10924115.001]
  • [Cites] Appl Environ Microbiol. 2001 Dec;67(12):5351-61 [11722879.001]
  • [Cites] J Biol Chem. 2006 Mar 17;281(11):7546-55 [16407248.001]
  • [Cites] Biochemistry. 2006 Apr 11;45(14):4351-61 [16584170.001]
  • [Cites] J Mol Biol. 2006 Dec 1;364(3):526-35 [17028023.001]
  • [Cites] PLoS Biol. 2007 Jun;5(6):e144 [17518518.001]
  • (PMID = 17993516.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Bicarbonates; 0 / Multiprotein Complexes; 142M471B3J / Carbon Dioxide; EC 4.1.1.39 / Ribulose-Bisphosphate Carboxylase
  • [Other-IDs] NLM/ PMC2223583
  •  go-up   go-down


6. Liu L, Wang X, Jacobson AJ: AlF.1,4-benzenedicarboxylate: synthesis and absorption properties. Dalton Trans; 2010 Feb 21;39(7):1722-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AlF(bdc), bdc = 1,4-benzenedicarboxylate, a new member of the family of MX(bdc) compounds has been synthesized under solvothermal conditions.
  • It is formed without H(2)bdc in the channels and substantial absorption capacity is observed in its as-synthesized form.
  • AlF(bdc) does not absorb water at ambient temperatures and shows absorption properties similar to VO(bdc).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM FLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449413.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1,4-benzenedicarboxylate; 0 / Aluminum Compounds; 0 / Organometallic Compounds; 0 / Phthalic Acids; Q80VPU408O / Fluorides; Z77H3IKW94 / aluminum fluoride
  •  go-up   go-down


7. Zou L, Mendez F, Martin-Orozco N, Peterson EJ: Defective positive selection results in T cell lymphopenia and increased autoimmune diabetes in ADAP-deficient BDC2.5-C57BL/6 mice. Eur J Immunol; 2008 Apr;38(4):986-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adhesion and degranulation promoting adapter protein (ADAP), a positive regulator of T cell receptor (TCR) signaling, is required for thymocyte development and T cell homeostasis.
  • To investigate the role of ADAP in a T cell-driven autoimmune response, we generated ADAP-deficient, BDC2.5 TCR transgenic, diabetes-prone (C57BL/6) mice (BDC/B6).
  • We observed a striking enhancement of diabetes incidence in ADAP-deficient mice, both in animals homozygous for I-Ag7, and in mice carrying one I-Ab allele (BDC/B6g7/b).
  • Consistent with a state of functional lymphopenia in ADAP-deficient BDC/B6g7/b mice, T cells display increased homeostatic proliferation.
  • Marked attenuation in cellularity of the CD4+ single-positive thymocyte compartment in ADAP-deficient BDC/B6g7/b animals suggests a mechanism for induction of the lymphopenia.
  • We conclude that inefficient positive selection in ADAP deficiency results in lymphopenia that leads to enhanced autoimmune diabetes in the BDC/B6g7/b model.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2001 Mar 1;166(5):3008-18 [11207250.001]
  • [Cites] Science. 2001 Sep 21;293(5538):2260-3 [11567140.001]
  • [Cites] Eur J Immunol. 1989 May;19(5):889-95 [2661244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14580-5 [15340148.001]
  • [Cites] J Exp Med. 2004 Jun 7;199(11):1479-89 [15184501.001]
  • [Cites] Cell. 2004 Apr 16;117(2):265-77 [15084263.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6954-60 [14662903.001]
  • [Cites] Immunol Rev. 2003 Apr;192:113-21 [12670399.001]
  • [Cites] Annu Rev Immunol. 2003;21:139-76 [12414722.001]
  • [Cites] Immunity. 2002 Dec;17(6):725-36 [12479819.001]
  • [Cites] Curr Opin Immunol. 2002 Jun;14(3):317-22 [11973129.001]
  • [Cites] Nat Immunol. 2001 Dec;2(12):1117-25 [11713466.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1025-31 [11668341.001]
  • [Cites] Science. 2001 Sep 21;293(5538):2263-5 [11567141.001]
  • [Cites] Cell. 1993 Sep 24;74(6):1089-100 [8402882.001]
  • [Cites] Cell. 1996 May 3;85(3):291-7 [8616883.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):387-96 [8760792.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11674-7 [9115214.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7493-8 [9207119.001]
  • [Cites] Immunity. 1997 Dec;7(6):873-83 [9430232.001]
  • [Cites] Mol Cell Biol. 2007 Jun;27(11):4070-81 [17403904.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):320-6 [17433869.001]
  • [Cites] Science. 2007 May 4;316(5825):754-8 [17478723.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(19):7130-44 [16980616.001]
  • [Cites] Eur J Immunol. 2006 Aug;36(8):2003-12 [16821236.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6681-9 [16709827.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6553-9 [16709812.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3517-26 [16294223.001]
  • [Cites] J Leukoc Biol. 2005 Sep;78(3):575-84 [15894586.001]
  • [Cites] Trends Immunol. 2005 Jan;26(1):5-8 [15629402.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):331-9 [9892615.001]
  • [Cites] J Exp Med. 1998 Feb 2;187(3):379-87 [9449718.001]
  • (PMID = 18383041.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI056016; United States / NIAID NIH HHS / AI / AI1056016-01; United States / NIAID NIH HHS / AI / AI056016-01; United States / NCI NIH HHS / CA / R44 CA105605; United States / NCI NIH HHS / CA / R44 CA105605-03; United States / NIAID NIH HHS / AI / R01 AI056016-01; United States / NCI NIH HHS / CA / CA105605-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Fyb protein, mouse
  • [Other-IDs] NLM/ NIHMS178752; NLM/ PMC2829296
  •  go-up   go-down


8. Meilikhov M, Yusenko K, Fischer RA: The adsorbate structure of ferrocene inside [Al(OH)(bdc)]x (MIL-53): a powder X-ray diffraction study. Dalton Trans; 2009 Jan 28;(4):600-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The adsorbate structure of ferrocene inside [Al(OH)(bdc)]x (MIL-53): a powder X-ray diffraction study.
  • Ferrocene is strongly adsorbed by the highly porous metal-organic framework compound [Al(OH)(bdc)l], (MIL-53; bdc = 1,4-benzenedicarboxylate).
  • The structure of the crystalline phase {[Fe(eta5-C5H5)2][Al(OH)(bdc)]2}x, was determined by X-ray powder diffraction and Rietveld methods.
  • The ferrocene molecules are arranged in a 1D chain-like fashion and their cyclopentadienyl rings are oriented almost parallel to the O3Al faces of the {AlO6}) octahedra without pi-stacking to the bdc.


9. Yang XP, Jones RA, Rivers JH, Lai RP: Syntheses, structures and luminescent properties of new lanthanide-based coordination polymers based on 1,4-benzenedicarboxylate (bdc). Dalton Trans; 2007 Sep 21;(35):3936-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Syntheses, structures and luminescent properties of new lanthanide-based coordination polymers based on 1,4-benzenedicarboxylate (bdc).
  • Reaction of 1,4-benzenedicarboxylic acid (1,4-H2BDC) with EuCl(3).6H2O in MeOH in the presence of Et3N and MeCN gives a mixture of the 3-D metal-organic-framework (MOF) materials [Eu2(1,4-BDC)3(MeOH)4].8MeOH (1) and 2-D [Eu(1,4-BDC)(MeOH)4].Cl.MeOH.0.25H2O (2).
  • Reaction of 1,4-H2BDC with Ln(NO3)(3).6H2O under similar conditions gave [Ln(BDC)NO3(MeOH)2].MeCN.H2O (Ln = Eu (5) and Gd (6)), which have 2-D framework structures.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893791.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Cardillo MR, Ippoliti F: Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol; 2007 Jan-Mar;20(1):37-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma.
  • Cytokines, notably the interleukins IL-6 and IL-10, have an important role in the development and progression of renal-cell carcinomas, acting in the host-tumor interaction and in tumor bulk.
  • To define the roles of the cytokines IL-6 and IL-10 and HSP-90 in the progression of renal-cell carcinoma we analyzed immunohistochemical expression of these proteins in human renal-cell carcinomas from 95 total nephrectomies.
  • IL-6, IL-10 and HSP-90 proteins were more strongly expressed in epithelium and stroma of the renal tumoral compartment than in adjacent normal peritumoral tissue.
  • The percentage of cells expressing IL-6, IL-10 and HSP-90 immunoreactivity was higher in benign epithelial tumors, than in normal peritumoral tissue, but lower than in renal-cell carcinomas.
  • Whereas HSP-90 immunoreactivity seemed higher in more aggressive histological phenotypes (collecting-duct carcinoma) of renal-cell carcinomas, IL-10 protein levels were higher in more advanced TNM stage (pT3) tumors.
  • Our observation suggests that IL-6 and IL-10 and HSP-90 may be useful markers associated with the development and progression of renal-cell carcinomas and have independent functional roles in this malignant condition.
  • [MeSH-major] Carcinoma / metabolism. HSP90 Heat-Shock Proteins / biosynthesis. Interleukin-10 / biosynthesis. Interleukin-6 / biosynthesis. Kidney / metabolism. Kidney Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346426.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


11. Bao YH, Liang YM, Gao GY, Pan YH, Luo QZ, Jiang JY: Bilateral decompressive craniectomy for patients with malignant diffuse brain swelling after severe traumatic brain injury: a 37-case study. J Neurotrauma; 2010 Feb;27(2):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abstract In this study we retrospectively analyzed the outcome of bilateral decompressive craniectomy (BDC) for 37 patients with bilateral malignant diffuse brain swelling following severe traumatic brain injury (TBI).
  • The intracranial pressure (ICP) and cerebral perfusion pressure (CPP) were measured before and after BDC, and Glasgow Outcome Scale (GOS) scores were measured after >6 months of follow-up.
  • The mean ICP was 37.7 +/- 6.4 mm Hg, and the mean CPP was 57.6 +/- 7.5 mm Hg before BDC.
  • Our data show that BDC offers immediate reductions in intracranial hypertension, and perhaps contributes to satisfactory outcomes in patients with bilateral diffuse brain swelling following severe TBI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715392.001).
  • [ISSN] 1557-9042
  • [Journal-full-title] Journal of neurotrauma
  • [ISO-abbreviation] J. Neurotrauma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Compérat EV, Vasiliu V, Ferlicot S, Camparo P, Sibony M, Vieillefond A: [Tumors of the kidneys: new entities]. Ann Pathol; 2005 Apr;25(2):117-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumeurs du rein: les nouvelles entités.
  • Since 1998 new entities have surfaced in renal tumor classification and have been included in the WHO 2004 classification.
  • In this article, we will discuss the following entities: multilocular clear cell renal carcinoma, Xp11 translocation carcinoma, low grade mucinous tubular carcinoma, epithelioid angiomyolipoma, benign mixed epithelial and stromal tumor.
  • We will investigate new concepts of hybrid oncocytoma and chromophobe renal cell carcinoma and the syndrome of Birt-Hogg-Dube which is associated to kidney tumors.
  • At least, we will touch on new elements in the Bellini carcinoma definition.
  • [MeSH-major] Kidney Neoplasms / classification. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Angiomyolipoma / pathology. Carcinoma / genetics. Carcinoma / pathology. Humans. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142163.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 77
  •  go-up   go-down


13. Burton AR, Vincent E, Arnold PY, Lennon GP, Smeltzer M, Li CS, Haskins K, Hutton J, Tisch RM, Sercarz EE, Santamaria P, Workman CJ, Vignali DA: On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes; 2008 May;57(5):1321-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Type 1 diabetes is mediated by T-cell entry into pancreatic islets and destruction of insulin-producing beta-cells.
  • The relative contribution of T-cells specific for different autoantigens is largely unknown because relatively few have been assessed in vivo.
  • RESEARCH DESIGN AND METHODS: We generated mice possessing a monoclonal population of T-cells expressing 1 of 17 T-cell receptors (TCR) specific for either known autoantigens (GAD65, insulinoma-associated protein 2 (IA2), IA2beta/phogrin, and insulin), unknown islet antigens, or control antigens on a NOD.scid background using retroviral-mediated stem cell gene transfer and 2A-linked multicistronic retroviral vectors (referred to herein as retrogenic [Rg] mice).
  • Three TCRs specific for unknown islet antigens produced a hierarchy of insulitogenic and diabetogenic potential (BDC-2.5 > NY4.1 > BDC-6.9), while a fourth (BDC-10.1) mediated dramatically accelerated disease, with all mice diabetic by day 33, well before full T-cell reconstitution (days 42-56).
  • Remarkably, as few as 1,000 BDC-10.1 Rg T-cells caused rapid diabetes following adoptive transfer into NOD.scid mice.
  • [MeSH-major] Autoantigens / adverse effects. Diabetes Mellitus, Type 1 / immunology. Islets of Langerhans / immunology. Receptors, Antigen, T-Cell / immunology. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299317.001).
  • [ISSN] 1939-327X
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NIDDK NIH HHS / DK / P30 DK57516; United States / NIDDK NIH HHS / DK / R01 DK052068; United States / NIAID NIH HHS / AI / U19 AI050864-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Receptors, Antigen, T-Cell; EC 4.1.1.15 / Glutamate Decarboxylase; EC 4.1.1.15 / glutamate decarboxylase 2
  •  go-up   go-down


14. Fakhrai N, Haitel A, Balassy C, Zielinski CC, Schmidinger M: Major response and clinical benefit following third-line treatment for Bellini duct carcinoma. Wien Klin Wochenschr; 2005 Jan;117(1-2):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major response and clinical benefit following third-line treatment for Bellini duct carcinoma.
  • Bellini duct carcinoma accounts for 1-3% of all renal carcinomas and is characterized by an aggressive course and extremely poor prognosis.
  • Conventional treatment for renal-cell carcinoma seems to be ineffective.
  • Since the histology of Bellini duct carcinoma is similar to urothelial carcinoma, chemotherapy for urothelial cancer might be more promising than conventional treatment.
  • We present a patient with renal carcinoma of the left kidney who underwent laparoscopic extrafascial nephrectomy and adrenalectomy.
  • Histopathologic work-up showed Bellini duct carcinoma (pT3a, NX, G3, R0 and M0).
  • Six courses of chemotherapy with cisplatin and gemcitabine were given, a treatment reported to be highly active in urothelial cancer.
  • The combination of cisplatin and gemcitabine was highly active in this patient with metastatic Bellini duct carcinoma, even given as third-line treatment.
  • Histopathologic characteristics should be a major criterion for treatment strategy in renal carcinoma, particularly in Bellini duct carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / drug therapy. Palliative Care / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986594.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 4Z8R6ORS6L / Thalidomide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Larsen RW, McManus GJ, Perry JJ 4th, Rivera-Otero E, Zaworotko MJ: Spectroscopic characterization of hydroxylated nanoballs in methanol. Inorg Chem; 2007 Jul 23;46(15):5904-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, the photophysical properties of self-assembled [Cu(2)(5-OH-bdc)(2)L(2)](12) [where (5-OH-bdc)(2-) = 5-hydroxybenzene-1,3-dicarboxylate and L is a dimethyl sulfoxide, methanol, or water ligand] hydroxylated nanoballs (OH-nanoball) were examined in methanol using optical absorption and steady-state and time-resolved fluorescence methods.
  • The emission from the OH-nanoball is significantly quenched relative to the free ligand [Phi(5-OH-H(2)bdc) = 0.014 and Phi(OH-nanoball) = (5.6 +/- 0.5) x 10-5].
  • The addition of bases such as imidazole results in an increase in the emission intensity of the OH-nanoball solution, indicating dissociation of the [Cu(2)(5-OH-bdc)(2)L(2)](12) units.
  • Although the mechanism of (5-OH-bdc)(2-) quenching within the OH-nanoball is not clear, it is likely due to interactions between the ligand pi system and the Cu d orbitals.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. METHANOL .
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • Hazardous Substances Data Bank. Water .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585758.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 059QF0KO0R / Water; 7YNJ3PO35Z / Hydrogen; Y4S76JWI15 / Methanol; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


16. Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, Dalrymple NC, Chintapalli KN: Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics; 2006 Nov-Dec;26(6):1795-806; discussion 1806-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation.
  • Renal cell carcinoma (RCC) is a cause of significant morbidity and mortality, with an estimated 35,000 new cases and 12,480 deaths in the United States in 2003.
  • Recent advances in imaging technology, pathology, urology, and oncology permit early diagnosis of RCC and facilitate optimal management.
  • The 2004 World Health Organization classification for renal neoplasms recognizes several distinct histologic subtypes of RCC.
  • These subtypes include clear cell RCC, papillary RCC, chromophobe RCC, hereditary cancer syndromes, multilocular cystic RCC, collecting duct carcinoma, medullary carcinoma, mucinous tubular and spindle cell carcinoma, neuroblastoma-associated RCC, Xp11.2 translocation-TFE3 carcinoma, and unclassified lesions.
  • Collecting duct carcinoma and renal medullary carcinoma are associated with aggressive clinical behavior and a poor prognosis.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / radiography. Image Enhancement / methods. Kidney Neoplasms / pathology. Kidney Neoplasms / radiography

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2006
  • (PMID = 17102051.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


17. Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO: Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A; 2008 Aug 26;105(34):12439-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice.
  • With the goal of identifying changes in gene expression in CD4(+) T cells during the development of diabetes in the nonobese diabetic (NOD) mouse, we used DNA microarrays to analyze gene expression in CD4(+) T cells from the pancreatic draining lymph nodes of NOD/BDC 2.5 T cell receptor transgenic and WT NOD mice at different ages.
  • At 4 and 6 weeks of age, we found up-regulation of a number of genes that are known to be induced by IFN-alpha.
  • Moreover, blockade of IFN-alpha receptor 1 in NOD mice by a neutralizing antibody at 2-3 weeks of age significantly delayed the onset and decreased the incidence of type 1 diabetes, increased the relative number of immature dendritic cells in the PLNs, and enhanced the ability of spleen CD4(+) T cells to produce IL-4 and IL-10.
  • These findings demonstrate that IFN-alpha in the PLNs is an essential initiator in the pathogenesis of type 1 diabetes in NOD mice.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2001 Mar 1;166(5):2961-9 [11207245.001]
  • [Cites] Annu Rev Immunol. 2005;23:447-85 [15771578.001]
  • [Cites] Nature. 2001 Dec 13;414(6865):792-8 [11742411.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4907-13 [11994440.001]
  • [Cites] J Exp Med. 2002 Aug 5;196(3):369-77 [12163565.001]
  • [Cites] Annu Rev Immunol. 2003;21:685-711 [12615891.001]
  • [Cites] J Exp Med. 2003 Apr 7;197(7):885-98 [12682109.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep 15;18(6):549-58 [12969081.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10872-7 [12960379.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1527-37 [14623908.001]
  • [Cites] Lancet. 1987 Dec 19;2(8573):1423-7 [2891993.001]
  • [Cites] Science. 1993 Jun 25;260(5116):1942-6 [8100367.001]
  • [Cites] Cell. 1993 Sep 24;74(6):1089-100 [8402882.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10494-8 [7504266.001]
  • [Cites] Lancet. 1994 May 7;343(8906):1167-8 [7910261.001]
  • [Cites] J Exp Med. 1994 Sep 1;180(3):995-1004 [8064245.001]
  • [Cites] Immunity. 1994 Sep;1(6):469-78 [7895158.001]
  • [Cites] Diabetes. 1995 Jun;44(6):658-64 [7540571.001]
  • [Cites] Am J Pathol. 1995 Nov;147(5):1193-9 [7485382.001]
  • [Cites] Diabetes. 1998 Jan;47(1):39-44 [9421372.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1947-53 [9712065.001]
  • [Cites] Diabetologia. 1998 Oct;41(10):1227-32 [9794112.001]
  • [Cites] Science. 1999 Jun 11;284(5421):1835-7 [10364556.001]
  • [Cites] J Interferon Cytokine Res. 1999 Aug;19(8):877-9 [10476932.001]
  • [Cites] Annu Rev Immunol. 2005;23:307-36 [15771573.001]
  • [Cites] Diabetes. 2005 Sep;54(9):2549-56 [16123342.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15995-6000 [16247001.001]
  • [Cites] J Interferon Cytokine Res. 2006 Nov;26(11):804-19 [17115899.001]
  • [Cites] Immunity. 2007 Aug;27(2):321-33 [17707128.001]
  • [Cites] J Autoimmun. 2001 Sep;17(2):119-25 [11591120.001]
  • (PMID = 18716002.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067592; United States / NIDDK NIH HHS / DK / R01 DK67592
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 130068-27-8 / Interleukin-10; 156986-95-7 / Receptor, Interferon alpha-beta; 207137-56-2 / Interleukin-4
  • [Other-IDs] NLM/ PMC2527930
  •  go-up   go-down


18. Wei GH, Yang J, Ma JF, Liu YY, Li SL, Zhang LP: Syntheses, structures and luminescent properties of zinc(II) and cadmium(II) coordination complexes based on new bis(imidazolyl)ether and different carboxylate ligands. Dalton Trans; 2008 Jun 21;(23):3080-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of mixed-ligand coordination complexes, namely [Zn(CA)(2)(BIE)] (1), [Zn(OX)(BIE)].H(2)O (2), [Zn(2)(m-BDC)(2)(BIE)(2)] (3), [Cd(m-BDC)(BIE)] (4), [Cd(5-OH-m-BDC)(BIE)] (5), [Zn(5-OH-m-BDC)(BIE)] (6), [Zn(2)(p-BDC)(2)(BIE)(2)].2.5H(2)O (7), [Cd(3)(p-BDC)(3)(BIE)] (8), [Cd(3)(BTC)(2)(BIE)(2)].0.5H(2)O (9) and [Zn(BTCA)(0.5)(BIE)] (10), where CA = cinnamate anion, OX = oxalate anion, m-BDC = 1,3-benzenedicarboxylate anion, 5-OH-m-BDC = 5-OH-1,3-benzenedicarboxylate anion, p-BDC = 1,4-benzenedicarboxylate anion, BTC = 1,3,5-benzenetricarboxylate anion, BTCA = 1,2,3,4-butanetetracarboxylate anion, and BIE = 2,2'-bis(1H-imidazolyl)ether, were synthesized under hydrothermal conditions.
  • In 4 and 5, m-BDC and 5-OH-m-BDC bridge Cd(II) atoms to give dimeric units, respectively, which are further linked by BIE ligands to form sql nets.
  • In 7, the BIE and p-BDC ligands link the Zn(ii) atoms to give a rare 3-fold interpenetrated 3-connected 10(3)-ths net.
  • Each rod is connected by the benzene rings of p-BDC in four directions into a simple alpha-Po topology.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521450.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Siebenbrock H: [Certified Medical Manager (CMM) -- more than only imparting knowledge. The qualifications offensive of the German Society of Surgeons for physicians in management positions]. Chirurg; 2008 Apr;Suppl:128-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Certified Medical Manager (CMM)--mehr als nur Wissensvermittlung Die Qualifikations-offensive des BDC für Arzte in Führungspositionen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985891.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M: Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol; 2005 Apr;18(4):535-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study.
  • Diagnostic use of antibodies against aquaporin water channel proteins and PAX-2, a nuclear transcription factor in renal development, was tested in 202 renal neoplasms, using tissue microarray technique.
  • Immunohistochemistry for aquaporin-1, aquaporin-2, PAX-2, CD10, and cytokeratin 7 was performed on 102 clear cell renal cell carcinomas, 44 papillary renal cell carcinomas (among them 34 type 1 and 10 type 2), 24 chromophobe renal cell carcinomas, three collecting duct carcinomas (carcinomas of the collecting ducts of Bellini), and 29 oncocytomas.
  • Aquaporin-1 expression was found in clear cell renal cell carcinomas and papillary renal cell carcinomas of both types (78 and 73%, respectively), but not in chromophobe renal cell carcinomas, collecting duct carcinomas, and oncocytomas.
  • PAX-2 and CD10 was found in the majority of clear cell renal cell carcinomas (88 and 85%, respectively) but only in few papillary renal cell carcinomas, chromophobe renal cell carcinomas and oncocytomas.
  • Decrease or loss of aquaporin-1 and PAX-2 was shown in higher grades compared to lower grades of clear cell renal cell carcinomas (P<0.0001 and <0.0245, respectively).
  • Cytokeratin 7 was rarely seen in clear cell renal cell carcinomas, type 2 papillary renal cell carcinomas, and oncocytomas, but was found in the majority of type 1 papillary renal cell carcinomas (97.1%) and chromophobe renal cell carcinomas (88%).
  • Aquaporin-1 and PAX-2 expression was found to correlate with nuclear grading for clear cell renal cell carcinomas but not for papillary renal cell carcinomas.
  • Aquaporin-1 and PAX-2 are reliable markers for clear cell renal cell carcinomas of lower grades but not for higher grades.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Aquaporin 1. Aquaporin 2. Aquaporins / biosynthesis. Blood Group Antigens. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA-Binding Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-7. Keratins / biosynthesis. Kidney / chemistry. Kidney / pathology. Neoplasm Staging. Neprilysin / biosynthesis. PAX2 Transcription Factor. Tissue Array Analysis / methods. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502805.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP1 protein, human; 0 / AQP2 protein, human; 0 / Aquaporin 2; 0 / Aquaporins; 0 / Biomarkers, Tumor; 0 / Blood Group Antigens; 0 / DNA-Binding Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Transcription Factors; 146410-94-8 / Aquaporin 1; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


21. Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH: MET expression in sporadic renal cell carcinomas. J Korean Med Sci; 2006 Aug;21(4):672-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MET expression in sporadic renal cell carcinomas.
  • Although germline mutations of met proto-oncogene on human chromosome 7q31-34 have been known as useful molecular markers of hereditary papillary renal cell carcinoma (RCC), the expression of MET, a product of met proto-oncogene, has not been fully studied in sporadic RCC, along with its clinical significance.
  • We investigated the expression of MET by immunohistochemistry in 182 cases of renal neoplasm encompassing 145 RCC, 25 urothelial carcinomas of renal pelvis, and 12 oncocytomas.
  • MET was diffusely and strongly expressed in 90% of papillary RCC, all collecting duct carcinomas, and 92% of urothelial carcinomas of renal pelvis.
  • In clear cell RCC, MET expression was positively correlated with high nuclear grade, presence of infiltrative growth, tumoral necrosis, papillary architecture, sarcomatoid component, tumoral involvement of the renal pelvis or ureter, involvement of the calyx, and lymphatic invasion.
  • In conclusion, diffuse and strong expression of MET in papillary RCC and collecting duct carcinoma might be helpful in discriminating from the other subtypes of RCC with tubular or papillary growth.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Proto-Oncogene Proteins / biosynthesis. Receptors, Growth Factor / biosynthesis
  • [MeSH-minor] Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Humans. Immunohistochemistry. Kidney Pelvis / chemistry. Kidney Pelvis / pathology. Neoplasm Staging. Proto-Oncogene Proteins c-met. Urothelium / chemistry. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] J Urol. 2002 Jul;168(1):51-5 [12050491.001]
  • [Cites] Int J Urol. 1998 Sep;5(5):436-40 [9781430.001]
  • [Cites] Virchows Arch. 1998 Dec;433(6):511-5 [9870683.001]
  • [Cites] J Urol. 1999 Mar;161(3):990-7 [10022739.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2343-50 [10327054.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):517-26 [10433944.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):957-62 [10357773.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jan;85(1):21-5 [3277171.001]
  • [Cites] J Pathol. 1988 Aug;155(4):277-87 [2459332.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):237-45 [2565618.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):415-9 [1824873.001]
  • [Cites] Science. 1992 Aug 28;257(5074):1258-61 [1387731.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):295-302 [8326547.001]
  • [Cites] J Cell Biol. 1993 Oct;123(1):223-35 [8408200.001]
  • [Cites] Adv Cancer Res. 1993;62:89-124 [8109322.001]
  • [Cites] J Cell Biol. 1995 Jan;128(1-2):171-84 [7822413.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1892-5 [8620510.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):212-7 [8682590.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):537-44 [9195569.001]
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):724-8 [9258068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11445-50 [9326629.001]
  • [Cites] Oncogene. 1998 Aug 13;17(6):733-9 [9715275.001]
  • [Cites] Oncogene. 2000 Feb 10;19(6):754-61 [10698493.001]
  • [Cites] Nature. 1987 May 21-27;327(6119):239-42 [2952888.001]
  • (PMID = 16891811.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  • [Other-IDs] NLM/ PMC2729889
  •  go-up   go-down


22. Xu G, Xie Y: Poly[aqua(mu2-benzene-1,4-dicarboxylato)(mu2-4,4'-bipyridine N,N'-dioxide)cadmium(II)], a threefold interpenetrating diamond net. Acta Crystallogr C; 2010 Aug;66(Pt 8):m201-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the title compound, [Cd(C(8)H(4)O(4))(C(10)H(8)N(2)O(2))(H(2)O)](n), (I), each Cd(II) atom is seven-coordinated in a distorted monocapped trigonal prismatic coordination geometry, surrounded by four carboxylate O atoms from two different benzene-1,4-dicarboxylate (1,4-bdc) anions, two O atoms from two distinct 4,4'-bipyridine N,N'-dioxide (bpdo) ligands and one water O atom.
  • The bpdo and 1,4-bdc ligands are on centers of inversion.
  • Each crystallographically unique Cd(II) center is bridged by the 1,4-bdc dianions and bpdo ligands to give a three-dimensional diamond framework containing large adamantanoid cages.
  • Three identical such nets are interlocked with each other, thus directly leading to the formation of a threefold interpenetrated three-dimensional diamond architecture.
  • To the best of our knowledge, (I) is the first example of a threefold interpenetrating diamond net based on both bpdo and carboxylate ligands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20679704.001).
  • [ISSN] 1600-5759
  • [Journal-full-title] Acta crystallographica. Section C, Crystal structure communications
  • [ISO-abbreviation] Acta Crystallogr C
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


23. Ahnfeldt T, Gunzelmann D, Loiseau T, Hirsemann D, Senker J, Férey G, Stock N: Synthesis and modification of a functionalized 3D open-framework structure with MIL-53 topology. Inorg Chem; 2009 Apr 6;48(7):3057-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and modification of a functionalized 3D open-framework structure with MIL-53 topology.
  • Aluminum aminoterephthalate Al(OH)[H(2)N-BDC] x 0.3 (H(2)N-H(2)BDC (denoted MIL-53-NH(2)(as)) was synthesized under hydrothermal conditions.
  • The treatment with DMF at 150 degrees C leads to Al(OH)[H(2)N-BDC] x 0.95 DMF (MIL-53-NH(2)(DMF)).
  • Upon cooling in air, the hydrated form Al(OH)[H(2)N-BDC] x 0.9 H(2)O (MIL-53-NH(2)(lt)) is obtained.
  • The MIL-53-NH(2)(lt) can be modified by postsynthetic functionalization using formic acid, and the corresponding amide Al(OH)[HC(O)N(H)-BDC] x H(2)O (MIL-53-NHCHO) is formed.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19245258.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Okuda H, Tei N, Shimizu K, Imazu T, Yoshimura K, Kiyohara H, Nakamura Y, Fujimura H: [Case report: collecting (Bellini) duct carcinoma during the follow-up for bladder cancer]. Hinyokika Kiyo; 2008 Oct;54(10):665-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report: collecting (Bellini) duct carcinoma during the follow-up for bladder cancer].
  • A 78-year-old man had undergone transurethral resection of bladder tumor (TUR-Bt) 6 times since he was diagnosed as having bladder cancer.
  • Past histology was urothelial carcinoma, pTa, G1-G2.
  • During the follow-up, recurrent bladder cancer was found.
  • Enhanced computed tomography and drip infusion pyelography revealed pelvic cancer with tumor embolus in the inferior vena cava.
  • The histopathological diagnosis was urothelial carcinoma of the bladder and Bellini duct carcinoma of the kidney, but in immunohistostaining surgical specimen of both bladder and kidney showed some similarities.
  • Several reports indicate an association between Bellini and urothelial carcinoma.
  • We describe the case of the Bellini duct carcinoma of the kidney during the follow-up for bladder cancer with possibility of the association between Bellini and urothelial carcinoma.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Second Primary / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Renal Cell. Humans. Male. Neoplasm Recurrence, Local


25. Pantuck AJ: Editorial comment on: Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol; 2007 Oct;52(4):1145-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: Collecting duct renal cell carcinoma: a matched analysis of 41 cases.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Tubules, Collecting / pathology


26. van der Kwast TH: Editorial comment on: Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol; 2007 Oct;52(4):1146
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: Collecting duct renal cell carcinoma: a matched analysis of 41 cases.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Tubules, Collecting / pathology


27. Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE: Effects of benefit design change across 5 disease states. Am J Manag Care; 2007 Jun;13(6 Pt 2):370-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the effects of benefit design change (BDC) on medication adherence and persistence (including switch in therapy), drug costs, and total healthcare costs.
  • METHODS: Continuously enrolled patients in 2001 and 2002 with allergic rhinitis, asthma, diabetes mellitus, hypertension, or osteoarthritis belonged to employer groups with or without a pharmacy BDC as of January 1, 2002.
  • RESULTS: Compared with the group without BDC, the proportion of patients who discontinued drug therapy was significantly greater in the BDC group among those with allergic rhinitis (67% vs 54%), asthma (66% vs 50%), osteoarthritis (61% vs 36%), and hypertension (39% vs 18%) (P < .05 for all).
  • Medication compliance was not affected by BDC.
  • The year-to-year pharmacy costs per patient in the BDC group decreased $305 for patients with osteoarthritis (P < .001) and $95 for patients with allergic rhinitis (P = .03).
  • There was no significant effect on overall healthcare costs in any disease state during the year following the BDC.
  • CONCLUSION: A pharmacy BDC may result in decreased pharmacy costs, with no effect on overall healthcare costs within 1 year for patients with allergic rhinitis, asthma, hypertension, or osteoarthritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17567238.001).
  • [ISSN] 1936-2692
  • [Journal-full-title] The American journal of managed care
  • [ISO-abbreviation] Am J Manag Care
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Xu G, Zhang X, Guo P, Pan C, Zhang H, Wang C: Mn(II)-based MIL-53 analogues: synthesis using neutral bridging mu2-ligands and application in liquid-phase adsorption and separation of C6-C8 aromatics. J Am Chem Soc; 2010 Mar 24;132(11):3656-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the case of 4,4'-bipridine-N,N'-dioxide (BPNO), the infinite manganese oxide chains were further interconnected by BPNO besides BDC, which allows 1D channels to be accessible for guest molecules.


29. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF: Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol; 2005 Nov;100(11):2426-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy.
  • OBJECTIVES: Preliminary uncontrolled studies of photodynamic therapy (PDT) of bile duct cancer (BDC) have shown astonishingly good results in the reduction of cholestasis, improvement of life quality, and potential improvement of survival time.
  • Therefore, we investigated the influence of PDT on survival time in advanced BDC in a randomized controlled study.
  • METHODS: Thirty-two patients with nonresectable BDC were randomized.
  • RESULTS: PDT group and the control group were comparable due to age, gender, performance status, bilirubin level, and BDC stage (Bismuth classification).
  • PDT has the potential to result in a changeover of current palliative treatment of BDC.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Palliative Care. Photochemotherapy / methods

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279895.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematoporphyrins; 0 / Photosensitizing Agents; 136219-06-2 / photosan III; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


30. Amghouz Z, Roces L, García-Granda S, García JR, Souhail B, Mafra L, Shi FN, Rocha J: Metal organic frameworks assembled from Y(III), Na(I), and chiral flexible-achiral rigid dicarboxylates. Inorg Chem; 2010 Sep 6;49(17):7917-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New chiral metal organic frameworks, assembled from Y(III), Na(I), and chiral flexible-achiral rigid dicarboxylate ligands, formulated as [NaY(Tart)(BDC)(H(2)O)(2)] (1) and [NaY(Tart)(biBDC)(H(2)O)(2)] (2) (H(2)Tart = Tartaric acid; H(2)BDC = Terephthalic acid; H(2)biBDC = Biphenyl-4,4'-dicarboxylic acid), were obtained as single phases under hydrothermal conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672844.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Brunner TB, Eccles CL: Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol; 2010 Dec;186(12):672-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
  • PURPOSE: this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC).
  • PATIENTS AND METHODS: a PubMed research identified clinical trials in BDC through April 1, 2010 including randomised controlled trials, SEER analyses and retrospective trials.
  • Adjuvant and palliative treatment options need to be chosen carefully since 50% of the patients are older than 70 years at diagnosis.
  • For patients with unresectable biliary tract carcinoma (BTC), palliative stenting was previously the treatment of choice.
  • CONCLUSION: both the literature and recent technical progress corroborate the role of radiotherapy in BDC offering chances for novel clinical trials.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / radiotherapy. Bile Ducts, Extrahepatic. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):788-97; discussion 797-8 [7794082.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):189-95 [16542787.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):954-7 [15239222.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):201-7 [15192792.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2210-8 [10829040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72 (2):582-8 [18793961.001]
  • [Cites] Ann Surg. 1994 Mar;219(3):267-74 [8147607.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74 [12095564.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1689-700 [14534886.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):125-31 [1312319.001]
  • [Cites] Lancet. 1992 Dec 19-26;340(8834-8835):1488-92 [1281903.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):605-8; discussion 608-9 [9409582.001]
  • [Cites] World J Surg. 2003 Feb;27(2):173-9 [12616432.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1612-8 [15532789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1087-92 [9392548.001]
  • [Cites] Gastrointest Endosc. 2003 Feb;57(2):178-82 [12556780.001]
  • [Cites] Hepatogastroenterology. 2008 Nov-Dec;55(88):1951-4 [19260456.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • [Cites] World J Surg. 1988 Feb;12(1):91-8 [2830731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1357-65 [14630274.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1402-7 [15726542.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Strahlenther Onkol. 2008 Jan;184(1):8-14 [18188517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):178-82 [17276614.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):571-8 [15890602.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):790-6 [16716757.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):581-7 [10701737.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):425-8 [10955877.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):414-9 [12243816.001]
  • [Cites] Gut. 1996 Dec;39(6):852-5 [9038668.001]
  • [Cites] Radiother Oncol. 2009 Aug;92(2):249-54 [19324442.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1495-501 [18472359.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):929-35 [9369143.001]
  • [Cites] Am J Surg. 1990 Jan;159(1):91-7; discussion 97-8 [1688486.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):702-4 [12232749.001]
  • [Cites] Hepatogastroenterology. 1995 Jul;42(3):265-8 [7590576.001]
  • [Cites] J Clin Oncol. 1996 Aug;14 (8):2311-5 [8708722.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):848-58 [17012047.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6):786-94 [11084070.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):483-8 [16242254.001]
  • [Cites] Am Surg. 2001 Sep;67(9):839-43; discussion 843-4 [11565760.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1191-8 [19201549.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(11):1835-7 [15553731.001]
  • [Cites] Strahlenther Onkol. 2009 Nov;185(11):736-42 [19899007.001]
  • [Cites] Cancer J. 2002 Jan-Feb;8(1):74-8 [11895206.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):148-53 [18805651.001]
  • [Cites] Br J Surg. 1995 Nov;82(11):1522-5 [8535808.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):986-95 [16733114.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):883-94 [73534.001]
  • [Cites] Strahlenther Onkol. 2004 Dec;180(12):751-7 [15592694.001]
  • [Cites] Med Phys. 1997 Jan;24(1):103-10 [9029544.001]
  • [Cites] Cancer. 2009 Nov 15;115(22):5175-83 [19637356.001]
  • [Cites] Acta Oncol. 2006;45(7):856-64 [16982550.001]
  • [Cites] Strahlenther Onkol. 2009 Nov;185(11):715-21 [19899003.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):63-7 [2153649.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Radiother Oncol. 2010 Jan;94(1):47-52 [19963295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):945-51 [8138448.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):331-8 [3104245.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21 [12095546.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1973 Jan;117(1):73-80 [4685535.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):855-61 [8040034.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Endoscopy. 2006 Aug;38(8):787-92 [17001568.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12 ):663-7 [19107347.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):61-6 [8961369.001]
  • [Cites] Am J Surg. 1991 Apr;161(4):454-8 [1709795.001]
  • (PMID = 21136029.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0700730
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  •  go-up   go-down


32. Hudson TE, Matin L, Li W: Binocular spatial induction for the perception of depth does not cross the midline. Proc Natl Acad Sci U S A; 2008 Nov 18;105(46):18006-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Binocular depth contrast (BDC), the induction of an appearance of visual pitch in a centrally located line by pitched-from-vertical flanking lines, has particularly been the subject of a good deal of attention in this regard.
  • In the present article, we show that BDC does not cross the median plane but is restricted to the side of the visual field containing a unilateral inducer.
  • We present a two-channel three-stage neuromathematical model that accounts quantitatively for present and previous BDC results and also accounts for a large number of the most prominent features of binocular pitch perception: Stage 1 of the differencing channel obtains the difference between the retinal orientations of the images in the two eyes separately for the inducer and the test line; stage 1 of the summing channel obtains the corresponding sums.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Physiol. 1968 Mar;195(1):215-43 [4966457.001]
  • [Cites] Perception. 2003;32(9):1073-92 [14651321.001]
  • [Cites] J Physiol. 1970 Sep;210(1):165-86 [5500775.001]
  • [Cites] Vision Res. 1975 Mar;15(3):389-99 [1136155.001]
  • [Cites] Science. 1976 May 7;192(4239):561-3 [1257791.001]
  • [Cites] Vision Res. 1976 Jan;16(1):79-82 [1258391.001]
  • [Cites] Vision Res. 1981;21(7):1017-23 [7314481.001]
  • [Cites] Percept Psychophys. 1983 Aug;34(2):121-30 [6634367.001]
  • [Cites] Percept Psychophys. 1988 Nov;44(5):473-83 [3226898.001]
  • [Cites] Vision Res. 1989;29(3):315-24 [2773342.001]
  • [Cites] Vision Res. 1990;30(11):1811-25 [2288092.001]
  • [Cites] Vision Res. 1991;31(10):1687-99 [1767491.001]
  • [Cites] Vision Res. 1992 Mar;32(3):499-512 [1604837.001]
  • [Cites] Vision Res. 1993 May;33(7):947-57 [8506638.001]
  • [Cites] J Vestib Res. 1995 Nov-Dec;5(6):499-518 [8589859.001]
  • [Cites] J Comp Neurol. 1995 Dec 11;363(2):161-76 [8642068.001]
  • [Cites] Vision Res. 1996 Jan;36(1):43-51 [8746241.001]
  • [Cites] Vision Res. 1996 Aug;36(15):2253-62 [8776490.001]
  • [Cites] J Comp Neurol. 1996 Mar 18;366(4):643-55 [8833114.001]
  • [Cites] J Comp Neurol. 1997 Mar 3;379(1):21-47 [9057111.001]
  • [Cites] Arch Ital Biol. 1997 Mar;135(2):169-82 [9101027.001]
  • [Cites] Nature. 1997 Sep 18;389(6648):280-3 [9305841.001]
  • [Cites] Vis Neurosci. 1997 Sep-Oct;14(5):981-7 [9364733.001]
  • [Cites] Spat Vis. 1998;11(3):261-78 [9584344.001]
  • [Cites] Perception. 1998;27(1):87-103 [9692090.001]
  • [Cites] Perception. 1998;27(2):129-45 [9709447.001]
  • [Cites] Perception. 1998;27(5):553-72 [10070555.001]
  • [Cites] J Neurosci. 1999 Jul 1;19(13):5602-18 [10377367.001]
  • [Cites] J Physiol. 1962 Jan;160:106-54 [14449617.001]
  • [Cites] Optom Wkly. 1962 Nov 22;53:2311-5 [14000225.001]
  • [Cites] Am J Psychol. 1946 Jan;59:111-26 [21015315.001]
  • [Cites] Perception. 1999;28(9):1121-45 [10694962.001]
  • [Cites] Vision Res. 2000;40(19):2605-19 [10958912.001]
  • [Cites] Vision Res. 2001 Feb;41(4):415-26 [11166045.001]
  • [Cites] Vision Res. 2003 Jan;43(1):1-6 [12505599.001]
  • [Cites] Exp Brain Res. 1968;6(4):391-410 [5721767.001]
  • (PMID = 19004809.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / F31 MH012401; United States / NEI NIH HHS / EY / R01 EY010534; United States / NIMH NIH HHS / MH / 1-F31-MH12401-01; United States / NEI NIH HHS / EY / EY 10534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2584671
  •  go-up   go-down


33. Gönül II, Cakr A, Sözen S, Ataoglu O, Alkibay T: A case of tubulocystic carcinoma simultaneously occurring with clear cell type renal cell carcinoma and micropapillary urothelial carcinoma of bladder. South Med J; 2009 Jul;102(7):754-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of tubulocystic carcinoma simultaneously occurring with clear cell type renal cell carcinoma and micropapillary urothelial carcinoma of bladder.
  • To our knowledge, this is the first report of a very rare tumor, a "tubulocystic carcinoma," simultaneously occurring with micropapillary urothelial carcinoma in the bladder and clear cell type renal cell carcinoma in the same kidney.
  • Tubulocystic carcinoma is a recently entitled tumor.
  • It had been thought to arise from the distal collecting duct for a period of time and was therefore named as a low-grade collecting duct carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology


34. Hausdorf S, Wagler J, Mossig R, Mertens FO: Proton and water activity-controlled structure formation in zinc carboxylate-based metal organic frameworks. J Phys Chem A; 2008 Aug 21;112(33):7567-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The contributions of terephthalic acid and Zn(2+)-coordinated water in N,N-diethylformamide (DEF) to the overall proton activity in the synthesis of MOF-5 (Zn4O(BDC)3, BDC = 1,4-benzenedicarboxylate) were quantitatively determined by combined electrochemical and UV-vis spectroscopic measurements.
  • It was found that the water-induced structural transition of MOF-5 to the hydroxide structure Zn3(OH)2(BDC)2 x 2 DEF (MOF-69c) can be reverted by a thermal treatment of the obtained compound and its subsequent exposure to anhydrous DEF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652430.001).
  • [ISSN] 1520-5215
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Matana A, Zaputović L, Lucin K, Kastelan ZM: Persistent and progressive ST segment elevation caused by myocardial metastasis. Tumori; 2006 Sep-Oct;92(5):452-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a case of a female patient with collecting duct carcinoma of the right kidney and myocardial metastasis.
  • Echocardiography and autopsy findings confirmed the diagnosis.
  • [MeSH-major] Heart Conduction System / physiopathology. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168443.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Chu CX, Zhang Y, Zhou H, Yuan AH: Poly[[(μ(2)-benzene-1,4-dicarboxyl-ato-κO,O:O,O)(μ(2)-di-4-pyridyldiazene-κN:N)cobalt(II)] N,N-dimethyl-formamide disolvate hemihydrate]. Acta Crystallogr Sect E Struct Rep Online; 2009;65(Pt 9):m1035-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly[[(μ(2)-benzene-1,4-dicarboxyl-ato-κO,O:O,O)(μ(2)-di-4-pyridyldiazene-κN:N)cobalt(II)] N,N-dimethyl-formamide disolvate hemihydrate].
  • In the title compound, {[Co(C(8)H(4)O(4))(C(10)H(8)N(4))]·2C(3)H(7)NO·0.5H(2)O}(n), the Co(II) atom is six-coordinated by four O atoms from two benzene-1,4-dicarboxyl-ate (H(2)bdc(2-)) groups and two N atoms from two 4,4'-azopyridine (4,4'-azpy, or di-4-pyridyldiazene) ligands, leading to a distorted octa-hedral geometry.
  • The structure consists of two-dimensional corrugated sheets with a 4(4) topology in an …ABAB… packing pattern stacking along the a axis.
  • 8.561 (2)  Å (Co⋯Co distance) along the a axis.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Nov 29;298(5599):1762-5 [12459583.001]
  • [Cites] Science. 2003 May 16;300(5622):1127-9 [12750515.001]
  • [Cites] Science. 2005 Aug 26;309(5739):1350-4 [16123294.001]
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • (PMID = 21577400.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2969999
  •  go-up   go-down


37. Rüggeberg JA: [Letter to the FPD president Dr. Guido Westerwelle from vice presidence of the Professional Society of German Surgeons Dr. Jörg-Andreas Rüggeberg regarding the significance of covering physicians]. Chirurg; 2007 Dec;Suppl:417
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Brief an den FPD-Vorsitzenden Dr. Guido Westerwelle vom Vizepräsidenten des BDC Dr. Jörg-Andreas Rüggeberg zum Thema Bedeutung der Belegärzte.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546568.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Letter
  • [Publication-country] Germany
  •  go-up   go-down


38. Inoue H, Nonomura N, Kojima Y, Shiba M, Oka D, Arai Y, Nakayama M, Takayama H, Nishimura K, Mori H, Okuyama A: Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis. Nephrol Dial Transplant; 2007 Jul;22(7):2052-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
  • BACKGROUND: Renal cell carcinoma (RCC) frequently occurs in patients with long-term dialysis.
  • Long-term dialysis causes distinctive pathological changes in the kidney, which is known as acquired cystic disease of the kidney (ACDK).
  • METHODS: Renal cancer tissues (eight clear cell, two papillary, one Bellini duct and three of the so-called dialysis-specific renal carcinomas) from 13 patients undergoing long-term dialysis were examined for somatic mutations of the VHL disease gene.
  • By means of laser capture microdissection, cancerous and surrounding non-cancerous renal tissues from dialytic patients were subjected to PCR-based direct sequencing of the VHL gene.
  • These three mutations were identified in clear cell carcinomas occurring in association with end-stage renal disease undergoing dialysis for 194, 147 and 125 months.
  • None of the non-tumour tissues or other carcinoma tissues analysed, including dialysis-specific carcinoma, possessed VHL gene mutations.
  • CONCLUSION: These results indicate that VHL tumour-suppressor gene mutation is involved in clear cell carcinoma in association with long-term dialysis.
  • [MeSH-major] Kidney Failure, Chronic / therapy. Kidney Neoplasms / genetics. Mutation. Renal Dialysis. Von Hippel-Lindau Tumor Suppressor Protein / genetics
  • [MeSH-minor] Adenine. Aged. Base Sequence. Carcinoma / genetics. Carcinoma / pathology. Carcinoma, Renal Cell / etiology. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Gene Deletion. Guanine. Humans. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438007.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5Z93L87A1R / Guanine; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein; JAC85A2161 / Adenine
  •  go-up   go-down


39. Arias LF, Bruneval P, Blanco J: Renin expression in adult renal epithelial tumors with granular cells. Pathol Res Pract; 2010 Nov 15;206(11):731-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renin expression in adult renal epithelial tumors with granular cells.
  • Renal cell tumors have been shown to be associated with secretory products, including renin, but the frequency of renin expression is not known.
  • To investigate renin expression in epithelial renal neoplasms, we examined a series of 89 adult renal tumors with granular cells using a monoclonal antiserum to detect the hormone by immunohistochemistry (IHC) and their association with hypertension.
  • Renin was detected in 31.6% of 38 chromophobe carcinomas and in 12.5% of 24 conventional carcinomas.
  • Renin was not detected in collecting duct carcinomas or in mucinous tubular and spindle cell carcinomas.
  • In conclusion, renin is frequently expressed in renal epithelial neoplasms with granular cells, mainly in oncocytomas, but this renin appears clinically inactive.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Renin / metabolism
  • [MeSH-minor] Adenoma, Oxyphilic / complications. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cytoplasm / metabolism. Cytoplasm / pathology. Cytoplasmic Granules / metabolism. Female. Humans. Hypertension / complications. Immunoenzyme Techniques. Kidney / metabolism. Kidney / surgery. Kidney Tubules, Collecting / metabolism. Kidney Tubules, Collecting / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20619546.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.23.15 / Renin; Oncocytoma, renal
  •  go-up   go-down


40. Wang X, Liu G, Zhang J, Chen Y, Lin H, Zheng W: A novel 3D Cd(II) metal-organic framework with an unprecedented (5,6)-connected topology based on isophthalate and 2-(3-pyridyl)imidazo[4,5-f]1,10-phenanthroline. Dalton Trans; 2009 Sep 28;(36):7347-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel three dimensional cadmium metal-organic framework [Cd3(1,3-BDC)3(PIP)2].8H2O (1) with an unprecedented (5,6)-connected topology has been synthesized from the hydrothermal reaction of cadmium(II) nitrate with the mixed ligands isophthalate acid (1,3-H2BDC) and 2-(3-pyridyl)imidazo[4,5-f]1,10-phenanthroline (PIP).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727451.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Tull ES, Sheu YT, Butler C, Cornelious K: Relationships between perceived stress, coping behavior and cortisol secretion in women with high and low levels of internalized racism. J Natl Med Assoc; 2005 Feb;97(2):206-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A higher mean perceived stress score (PSS) and greater tendency to use "restraint," "denial" and "behavioral disengagement" (defeated) coping (BDC) styles were found among women with high INR compared to those with low INR.
  • In the combined sample, PSS and BDC were significantly correlated with an indicator of dysregulation of cortisol.

  • MedlinePlus Health Information. consumer health - Stress.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychosom Med. 2003 Sep-Oct;65(5):836-41 [14508029.001]
  • [Cites] Diabet Med. 1999 May;16(5):373-83 [10342336.001]
  • [Cites] J S C Med Assoc. 1979 Nov;75(11):501-9 [120470.001]
  • [Cites] Paediatr Perinat Epidemiol. 2000 Apr;14(2):127-35 [10791655.001]
  • [Cites] Obes Res. 2000 Sep;8(6):445-50 [11011911.001]
  • [Cites] Horm Metab Res. 2000 Nov-Dec;32(11-12):521-5 [11246819.001]
  • [Cites] J Endocrinol Invest. 2001 Mar;24(3):159-65 [11314744.001]
  • [Cites] Diabetes Care. 2001 Aug;24(8):1498 [11473095.001]
  • [Cites] J Natl Med Assoc. 2002 Mar;94(3):143-8 [11918383.001]
  • [Cites] Diabetes Metab. 2003 Sep;29(4 Pt 2):6S9-18 [14502096.001]
  • [Cites] J Health Soc Behav. 1983 Dec;24(4):385-96 [6668417.001]
  • [Cites] J Pers Soc Psychol. 1986 May;50(5):992-1003 [3712234.001]
  • [Cites] Soc Sci Med. 1988;26(3):309-17 [3279520.001]
  • [Cites] Int J Addict. 1990 Nov;25(11):1287-300 [2090628.001]
  • [Cites] Int J Addict. 1990 Dec;25(12):1415-27 [2094681.001]
  • [Cites] Endocrinology. 1992 Aug;131(2):585-94 [1322275.001]
  • [Cites] Psychoneuroendocrinology. 1994;19(4):313-33 [8047637.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jun;83(6):1853-9 [9626108.001]
  • [CommentIn] J Natl Med Assoc. 2005 Apr;97(4):583-4 [15868780.001]
  • (PMID = 15712783.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / 5T37 TW00038-07; United States / NIDDK NIH HHS / DK / DK46204
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC2568780
  •  go-up   go-down


42. Sakura M, Masuda H, Saito K, Koga F, Kawakami S, Kihara K: Collecting duct carcinoma with acquired cystic disease of the kidney in a long-term hemodialysis patient. Int J Urol; 2008 Jan;15(1):93-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma with acquired cystic disease of the kidney in a long-term hemodialysis patient.
  • We report a very rare case of collecting or Bellini duct carcinoma (CDC) found in a 60-year-old male who had received hemodialysis therapy for 21 years.
  • Screening with ultrasonography revealed a solid tumor originating from the cyst wall in the right kidney with acquired cystic disease of the kidney.
  • Subsequent computed tomography (CT) and angiography could not detect another renal tumor.
  • The tumor detected preoperatively was composed of papillary renal cell tumor (RCC) and multiple clear cell carcinoma, pathologically.
  • The histological diagnosis was multiple clear cell carcinomas.
  • [MeSH-major] Carcinoma, Renal Cell / etiology. Kidney Diseases, Cystic / etiology. Kidney Neoplasms / etiology. Renal Dialysis / adverse effects
  • [MeSH-minor] Fatal Outcome. Glomerulonephritis / therapy. Humans. Kidney Failure, Chronic / therapy. Male. Middle Aged. Nephrectomy


43. Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF: Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer; 2009 Jan;7(1):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.
  • BACKGROUND: Cytotoxic chemotherapy has not been well investigated in non-clear-cell renal cell carcinoma (RCC).
  • RESULTS: Seventeen patients were enrolled, of which 16 patients had papillary and 1 had collecting duct histology.
  • The patient with collecting duct histology had a complete response, but no responses were observed in patients with papillary histology and the trial was thus terminated early.
  • Future studies should explore the role of this or similar regimens in collecting duct carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy


44. Hou L, Lin YY, Chen XM: Porous metal-organic framework based on mu4-oxo tetrazinc clusters: sorption and guest-dependent luminescent properties. Inorg Chem; 2008 Feb 18;47(4):1346-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A three-dimensional, highly porous metal-organic framework [Zn 4O(bdc)(bpz) 2].4DMF.6H 2O ( 1) (bdc = 1,4-benzenedicarboxylate, bpz = 3,3',5,5'-tetramethyl-4,4'-bipyrazolate) constructed by Zn 4O clusters with bdc and bpz linkers, has been prepared and structurally characterized.

  • Hazardous Substances Data Bank. TOLUENE .
  • Hazardous Substances Data Bank. ZINC OXIDE .
  • Hazardous Substances Data Bank. METHANOL .
  • Hazardous Substances Data Bank. BENZENE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205303.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Pyrazoles; 0 / Solvents; 0 / zinc benzenedicarboxylate; 3FPU23BG52 / Toluene; J64922108F / Benzene; SOI2LOH54Z / Zinc Oxide; Y4S76JWI15 / Methanol
  •  go-up   go-down


45. Tamai H, Takiguchi Y, Oka M, Shingaki N, Enomoto S, Shiraki T, Furuta M, Inoue I, Iguchi M, Yanaoka K, Arii K, Shimizu Y, Nakata H, Shinka T, Sanke T, Ichinose M: Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors. J Ultrasound Med; 2005 Dec;24(12):1635-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors.
  • OBJECTIVE: The purpose of this study was to evaluate the usefulness of contrast-enhanced ultrasonography (CEUS) in the diagnosis of solid renal tumors.
  • METHODS: Twenty-nine patients with solid tumors detected on gray scale ultrasonography underwent resection for suspected renal malignancy.
  • Findings of arterial phase contrast computed tomography (CT) and CEUS were compared for each diagnosis.
  • RESULTS: Histopathologic examination of resected lesions showed malignancy in 26 patients (clear cell carcinoma, n = 18; papillary renal cell carcinoma, n = 6; collecting duct carcinoma, n = 1; and infiltrative urothelial carcinoma, n = 1) and benign tumors in 3 patients (oncocytoma, n = 2; and angiomyolipoma, n = 1).
  • Positive predictive values of CEUS and contrast CT in the diagnosis of renal malignancy were 100% and 82.8%, respectively.
  • Among clear cell carcinomas, hypervascularity was observed on contrast CT in 16 of 18 patients and on CEUS in 17 of 18 patients.
  • On the basis of hypervascularity, diagnostic sensitivity values for clear cell carcinoma were 94.4% for CEUS and 88.9% for contrast CT, whereas specificity values were 45.5% for CEUS and 72.7% for contrast CT.
  • Among papillary cell carcinomas, contrast CT showed avascular lesions in 4 of 6 patients.
  • However, CEUS showed blood flow in these lesions, leading to diagnosis of hypovascular renal tumors.
  • CONCLUSIONS: Contrast-enhanced ultrasonography was more sensitive for detecting slight tumor blood flow than contrast CT and was useful in preoperatively diagnosing malignant hypovascular renal tumors but was less so for hypervascular renal tumors.
  • [MeSH-major] Contrast Media. Image Enhancement / methods. Kidney Neoplasms / radiography. Kidney Neoplasms / ultrasonography. Neovascularization, Pathologic / radiography. Neovascularization, Pathologic / ultrasonography. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301719.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


46. Farah R, Ben-Izhak O, Munichor M, Cohen H: Low-grade renal collecting duct carcinoma. A case report with histochemical, immunohistochemical, and ultrastructural study. Ann Diagn Pathol; 2005 Feb;9(1):46-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade renal collecting duct carcinoma. A case report with histochemical, immunohistochemical, and ultrastructural study.
  • We report a rare tumor called low-grade renal collecting duct carcinoma.
  • Grossly, the tumor consisted of multiple cysts and solid white nodules, measuring 10 cm in diameter and occupying most of the renal parenchyma.
  • This tumor occurs in collecting ducts and the tumor cells were positive for epithelial membrane antigen, high-molecular-weight keratin, CD15, and mitochondrial antibody and negative for CD10.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Tubules, Collecting / pathology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692951.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Mucin-1
  •  go-up   go-down


47. Croft KE, Duff MC, Kovach CK, Anderson SW, Adolphs R, Tranel D: Detestable or marvelous? Neuroanatomical correlates of character judgments. Neuropsychologia; 2010 May;48(6):1789-801
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vmPFC, HC, and brain-damaged comparison (BDC) participants made moral judgments about unfamiliar persons before and after exposure to social scenarios depicting the persons engaged in morally good, bad, or neutral behaviors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Neuroimage. 1997 Jan;5(1):13-30 [9038281.001]
  • [Cites] J Clin Exp Neuropsychol. 2008 Nov;30(8):931-45 [18608659.001]
  • [Cites] Nat Neurosci. 1999 Nov;2(11):1032-7 [10526345.001]
  • [Cites] Int Rev Neurobiol. 2004;62:159-93 [15530572.001]
  • [Cites] Cogn Affect Behav Neurosci. 2004 Sep;4(3):307-16 [15535166.001]
  • [Cites] Cereb Cortex. 2000 Mar;10(3):295-307 [10731224.001]
  • [Cites] J Pers Soc Psychol. 2002 Nov;83(5):1051-65 [12416911.001]
  • [Cites] Nat Rev Neurosci. 2003 Mar;4(3):165-78 [12612630.001]
  • [Cites] J Cogn Neurosci. 2003 Apr 1;15(3):324-37 [12729486.001]
  • [Cites] Brain. 2003 Jul;126(Pt 7):1691-712 [12805109.001]
  • [Cites] Brain. 2003 Aug;126(Pt 8):1790-800 [12805102.001]
  • [Cites] J Pers Soc Psychol. 2003 Oct;85(4):594-604 [14561114.001]
  • [Cites] Neuron. 2004 Feb 19;41(4):653-62 [14980212.001]
  • [Cites] Science. 2004 May 21;304(5674):1167-70 [15155951.001]
  • [Cites] J Pers Soc Psychol. 2004 Oct;87(4):482-93 [15491273.001]
  • [Cites] J Exp Psychol Learn Mem Cogn. 1985 Jan;11(1):22-36 [3156951.001]
  • [Cites] Neurology. 1985 Dec;35(12):1731-41 [4069365.001]
  • [Cites] Behav Brain Res. 1990 Dec 14;41(2):81-94 [2288668.001]
  • [Cites] Neuropsychologia. 1991;29(12):1241-9 [1791934.001]
  • [Cites] Prog Exp Pers Psychopathol Res. 1994;:285-311 [8044207.001]
  • [Cites] Neurology. 1996 May;46(5):1231-8 [8628458.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1996 Oct 29;351(1346):1413-20 [8941953.001]
  • [Cites] Nat Rev Neurosci. 2005 Oct;6(10):799-809 [16276356.001]
  • [Cites] Brain Res. 2006 Mar 24;1079(1):25-35 [16507301.001]
  • [Cites] J Int Neuropsychol Soc. 2006 Mar;12(2):224-35 [16573856.001]
  • [Cites] J Clin Exp Neuropsychol. 2006 May;28(4):457-76 [16624778.001]
  • [Cites] Neuropsychologia. 2006;44(8):1315-24 [16513144.001]
  • [Cites] J Cogn Neurosci. 2006 Jun;18(6):871-9 [16839295.001]
  • [Cites] Neuropsychologia. 2007 Jan 7;45(1):163-73 [16759672.001]
  • [Cites] Annu Rev Psychol. 2007;58:259-89 [17002553.001]
  • [Cites] J Neurosci. 2007 Jan 24;27(4):951-6 [17251437.001]
  • [Cites] Nature. 2007 Apr 19;446(7138):908-11 [17377536.001]
  • [Cites] Annu Rev Neurosci. 2007;30:31-56 [17417936.001]
  • [Cites] Brain Lang. 2008 Jul;106(1):41-54 [18078671.001]
  • [Cites] Soc Cogn Affect Neurosci. 2008 Sep;3(3):195-203 [19015111.001]
  • [Cites] Neuropsychologia. 2009 Jun;47(7):1686-93 [19397863.001]
  • [Cites] J Pers Soc Psychol. 1998 Oct;75(4):887-900 [9825526.001]
  • (PMID = 20211193.001).
  • [ISSN] 1873-3514
  • [Journal-full-title] Neuropsychologia
  • [ISO-abbreviation] Neuropsychologia
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR000059-466839; United States / NINDS NIH HHS / NS / P50 NS019632; United States / NIDA NIH HHS / DA / R01 DA022549-05; United States / NIDA NIH HHS / DA / R01 DA022549-04; United States / NIDA NIH HHS / DA / R01 DA022549; United States / NCRR NIH HHS / RR / M01 RR000059-466839; United States / NIDA NIH HHS / DA / R01 DA022549-04S1; United States / NIDA NIH HHS / DA / R01 DA022549-01; United States / NINDS NIH HHS / NS / P50 NS19632; United States / NIDA NIH HHS / DA / R01 DA022549-03; United States / NIMH NIH HHS / MH / R01 MH080721; United States / NCRR NIH HHS / RR / M01 RR000059; United States / NIMH NIH HHS / MH / R01 MH080721-04; United States / NIDA NIH HHS / DA / R01 DA022549-02; United States / NINDS NIH HHS / NS / NS019632-230003; United States / NINDS NIH HHS / NS / P01 NS019632; United States / NINDS NIH HHS / NS / P01 NS019632-230003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS187296; NLM/ PMC2862792
  •  go-up   go-down


48. Wang W, Yu GH, Qu GM, Yao WD, Jiang L: [Renal Bellini's collecting duct carcinoma: report of a case]. Zhonghua Bing Li Xue Za Zhi; 2010 Sep;39(9):631
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal Bellini's collecting duct carcinoma: report of a case].
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Medullary / pathology. Diagnosis, Differential. Humans. Keratins / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Squamous Cell / pathology. Nephrectomy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092594.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 68238-35-7 / Keratins
  •  go-up   go-down


49. Mitchell PB, Johnston AK, Corry J, Ball JR, Malhi GS: Characteristics of bipolar disorder in an Australian specialist outpatient clinic: comparison across large datasets. Aust N Z J Psychiatry; 2009 Feb;43(2):109-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reports on findings from the Black Dog Institute Bipolar Disorders Clinic (BDI-BDC) and compares this dataset with the predominantly outpatient Stanley Foundation Bipolar Disorders Network (SFBN) and Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) samples.
  • METHODS: A total of 217 patients with DSM-IV bipolar disorder were assessed in detail in the BDI-BDC using a series of standardized and non-standardized structured interviews.
  • The SFBN subjects reported higher numbers of overall episodes, but psychotic features and suicide attempts were less common than in the BDI-BDC sample.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153918.001).
  • [ISSN] 1440-1614
  • [Journal-full-title] The Australian and New Zealand journal of psychiatry
  • [ISO-abbreviation] Aust N Z J Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


50. Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, Cucinotta D, Galluzzo A, Falorni A, Dotta F: Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes; 2008 May;57(5):1276-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2.
  • OBJECTIVE: The presence of autoantibodies to islet antigens GAD and/or tyrosine phosphatase 2 (IA-2) in type 2 diabetic patients (latent autoimmune diabetes in adults [LADA]) identifies subjects at high risk to develop insulin dependency.
  • The aim of this study was to dissect humoral anti-IA-2 immune response in Caucasian LADA patients, identifying the most sensitive construct to evaluate IA-2 immunoreactivity and comparing LADA IA-2 epitope specificities to those found in type 1 diabetes.
  • RESEARCH DESIGN AND METHODS: We analyzed 177 LADA and 978 type 2 diabetic patients with different disease duration, collected in a nationwide Italian survey, the Non-Insulin Requiring Autoimmune Diabetes (NIRAD) study aimed at assessing prevalence and characteristics of autoimmune diabetes in type 2 diabetic patients and 106 newly diagnosed type 1 diabetic patients (53 children, 53 adults).
  • By radioimmunoassay, we analyzed humoral immunoreactivity to seven IA-2 constructs: IA-2(PTP (687-979)), IA-2((761-964)), IA-2((256-760)), IA-2(JM (601-630)), IA-2(IC (605-979)), IA-2(BDC (256-556:630-979)), and IA-2(FL (1-979)).
  • RESULTS: IA-2((256-760)) fragment was identified as the marker with the highest sensitivity for detection of humoral IA-2 immunoreactivity in LADA patients, identifying IA-2 autoantibodies in approximately 30% of GAD antibody (GADA)-positive LADA patients and in 3.4% of GADA-negative type 2 diabetic patients.
  • LADA IA-2((256-760))A positivity was associated with an increased frequency of autoimmune diabetes HLA-susceptible genotypes and with a higher risk for developing thyroid autoimmunity compared with autoantibody-negative type 2 diabetic patients.
  • At disease diagnosis, adult-onset type 1 diabetic and LADA patients showed a lower IA-2 COOH-terminal immunoreactivity compared with childhood-onset type 1 diabetic patients.
  • [MeSH-major] Autoantibodies / blood. Diabetes Mellitus, Type 2 / immunology. Islets of Langerhans / immunology. Peptide Fragments / chemistry. Protein Tyrosine Phosphatases / chemistry


51. Kuhlhoff F: [Comment on BDC-Chirurg Heft 4, 2007, S. 80 ff. "New specialist for orthopedics and trauma surgery"]. Chirurg; 2007 May;Suppl:171
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comment on BDC-Chirurg Heft 4, 2007, S. 80 ff. "New specialist for orthopedics and trauma surgery"].
  • [Transliterated title] Zu BDC-Chirurg Heft 4, 2007, S. 80 ff. "Neuer Facharzt fur Orthopadie und Unfallchirurgie".

  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18062039.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Letter
  • [Publication-country] Germany
  •  go-up   go-down


52. Zalatnai A: [Diagnostic difficulties in kidney cancer filling up the retroperitoneal space]. Orv Hetil; 2005 Apr 10;146(15):701-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic difficulties in kidney cancer filling up the retroperitoneal space].
  • An autopsy case of a huge, rapidly progressive Bellini duct carcinoma is presented.
  • The author discusses the pitfalls of diagnosis from clinicopathological point of view.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting / pathology. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Autopsy. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15895794.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


53. Kitano H, Anraku Y, Shinohara H: Sensing capabilities of colloidal gold monolayer modified with a phenylboronic acid-carrying polymer brush. Biomacromolecules; 2006 Apr;7(4):1065-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A dithiolated random copolymer with pendent phenylboronic acid residues [Cys-poly(3-acrylamidophenylboronic acid-co-N,N-dimethylaminopropyl methacrylamide), Cys-poly(APBA-co-DMAPMA)] that shows the abilities of initiation, transfer, and termination (iniferter) was obtained by using a benzyl N,N-diethyldithiocarbamoyl (BDC) derivative.

  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16602722.001).
  • [ISSN] 1525-7797
  • [Journal-full-title] Biomacromolecules
  • [ISO-abbreviation] Biomacromolecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Colloids; 0 / Membranes, Artificial; 0 / Polymers; 7440-57-5 / Gold; L12H7B02G5 / benzeneboronic acid
  •  go-up   go-down


54. Sugiura S, Makiyama K, Nakaigawa N, Yao M, Kubota Y, Oshiro H: Collecting duct carcinoma producing granulocyte-colony-stimulating factor (G-CSF). Int J Urol; 2007 Jun;14(6):555-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma producing granulocyte-colony-stimulating factor (G-CSF).
  • We present a 67-year-old male with a rare case of collecting duct carcinoma producing granulocyte colony-stimulating factor.
  • Laboratory testing showed leukocytosis and computed tomography revealed a left renal mass.
  • The histopathological diagnosis was collecting duct carcinoma producing granulocyte-colony-stimulating factor.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / metabolism. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Kidney Tubules, Collecting / pathology. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593104.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8UQ3W6JXAN / nedaplatin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


55. Han Y, Li X, Li L, Ma C, Shen Z, Song Y, You X: Structures and properties of porous coordination polymers based on lanthanide carboxylate building units. Inorg Chem; 2010 Dec 6;49(23):10781-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of 3-D lanthanide porous coordination polymers, [Ln(6)(BDC)(9)(DMF)(6)(H(2)O)(3)·3DMF](n) [Ln = La, 1; Ce, 2; Nd, 3], [Ln(2)(BDC)(3)(DMF)(2)(H(2)O)(2)](n) [Ln = Y, 4; Dy, 5; Eu, 6], [Ln(2)(ADB)(3)(DMSO)(4)·6DMSO·8H(2)O](n) [Ln = Ce, 7; Sm, 8; Eu, 9; Gd, 10], {[Ce(3)(ADB)(3)(HADB)(3)]·30DMSO·29H(2)O}(n) (11), and [Ce(2)(ADB)(3)(H(2)O)(3)](n) (12) (H(2)BDC = benzene-1,4-dicarboxylic acid and H(2)ADB = 4,4'-azodibenzoic acid), have been synthesized and characterized.
  • Compounds 7-10 are all 3-D interpenetrating structures with the CaB6-type topology structure.
  • Compound 11 is constructed by ADB spacers and trinulcear Ce nodes with a NaCl-type topology structure and a 1.9-nm open channel system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21028893.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Kamath AV, Wang J, Lee FY, Marathe PH: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol; 2008 Mar;61(3):365-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the routes of excretion were investigated after administration of dasatinib to bile duct cannulated (BDC) rats.
  • In BDC rats, less than 15% of an intravenous dose was excreted unchanged in urine, bile, and the gastrointestinal tract, suggesting that dasatinib is cleared primarily via metabolism.
  • However, in vivo studies in P-gp knockout mice versus wild-type mice showed no difference in the amount of dasatinib remaining unabsorbed in the gastrointestinal tract, suggesting that P-gp may not be responsible for the incomplete bioavailability.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17429625.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / P-Glycoprotein; 0 / Pyrimidines; 0 / Thiazoles; 2616-64-0 / Uridine Diphosphate Glucuronic Acid; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr; RBZ1571X5H / Dasatinib
  •  go-up   go-down


57. Atamna H, Newberry J, Erlitzki R, Schultz CS, Ames BN: Biotin deficiency inhibits heme synthesis and impairs mitochondria in human lung fibroblasts. J Nutr; 2007 Jan;137(1):25-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four of the 5 biotin-dependent carboxylases (BDC) are in the mitochondria.
  • BDC replace intermediates in the Krebs [tricarboxylic acid (TCA)] cycle that are regularly removed for the synthesis of key metabolites such as heme or amino acids.
  • Biotin-deficient primary human lung fibroblasts (IMR90) lost their BDC and senesced before biotin-sufficient cells.

  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • Hazardous Substances Data Bank. BIOTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17182796.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / K05 AT001323; United States / NIMHD NIH HHS / MD / P60 MD00222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oxidants; 42VZT0U6YR / Heme; 6SO6U10H04 / Biotin
  •  go-up   go-down


58. Davies RP, Less RJ, Lickiss PD, White AJ: Framework materials assembled from magnesium carboxylate building units. Dalton Trans; 2007 Jun 28;(24):2528-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four coordination polymers containing magnesium metal nodes and di- or tricarboxylic acid organic connectors have been synthesised and structurally characterised with the aid of single crystal X-ray diffraction.
  • Mg3(bdc)3(DMA)4 (1) and Mg3(bdc)3(EtOH)2 (2) were prepared from the 1 : 1 reaction of 1,4-benzenedicarboxylic acid (H(2)bdc) with Mg(NO3)2.6H2O in dimethylacetamide (DMA) or EtOH respectively.
  • These tri-magnesium nodes are joined by the bdc ligands in 1 to give a 2D layered structure with coordinated DMA solvent molecules between the layers, whereas in 2 they stack end-on to form a novel 3D network containing 1D Mg carboxylate chains.
  • Both 1 and 2 are moderately hygroscopic, and powder X-ray diffraction and thermogravimetric analysis studies show them to be interconvertible with Mg(bdc) and the hydrated complex Mg(bdc)(H2O)2 via a series of solid-state reactions.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17563788.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Feng JY, Liu ZQ: Phenolic and enolic hydroxyl groups in curcumin: which plays the major role in scavenging radicals? J Agric Food Chem; 2009 Nov 25;57(22):11041-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1,7-bis(4-benzyloxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (BEC), 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol (OHC), 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione (THC), and 1,7-bis(3,4-dihydroxyphenyl)-1,6-heptadiene-3,5-dione (BDC) are synthesized to determine the antioxidant activities by using antiradical assays against 2,2'-diphenyl-1-picrylhydrazyl (DPPH) radical, galvinoxyl radical, and 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonate) cation radical (ABTS*+) and by protecting DNA and erythrocyte against 2,2'-azobis(2-amidinopropane hydrochloride) (AAPH) induced oxidation.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736944.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Benzhydryl Compounds; 0 / Benzothiazoles; 0 / Biphenyl Compounds; 0 / Free Radical Scavengers; 0 / Phenols; 0 / Picrates; 0 / Sulfonic Acids; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl; 28752-68-3 / 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid; 9007-49-2 / DNA; IT942ZTH98 / Curcumin; W07Q6T5546 / galvinoxyl
  •  go-up   go-down


60. Srigley JR, Delahunt B: Uncommon and recently described renal carcinomas. Mod Pathol; 2009 Jun;22 Suppl 2:S2-S23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon and recently described renal carcinomas.
  • Major consensus conferences held over a decade ago laid the foundations for the current (2004) WHO classification of renal carcinoma.
  • Clear cell, papillary and chromophobe carcinomas account for 85-90% carcinomas seen in routine practice.
  • The remaining 10-15% of carcinomas consist of rare sporadic and hereditary tumors, some of which had been long recognized, but many of which only emerged as distinct entities in the decade leading up to the WHO publication.
  • Collecting-duct carcinoma is a rare, often lethal form of carcinoma.
  • Medullary carcinoma associated with sickle cell trait, has emerged as a distinctive tumor showing some overlapping features with upper tract urothelial carcinoma.
  • Mucinous tubular and spindle-cell carcinoma and tubulocystic carcinoma were earlier considered as patterns of low-grade collecting-duct carcinoma, but are now recognized as separate tumor entities.
  • Carcinomas associated with somatic translocations of TFE3 and TFEB comprise a significant proportion of pediatric renal carcinomas.
  • Oncocytoid renal carcinomas in neuroblastoma survivors was recognized as a unique tumor category in the WHO classification.
  • Renal carcinoma associated with end-stage renal disease is now recognized as having distinct morphological patterns and behavior.
  • In addition there is a group of rare recently described carcinomas, including clear cell papillary carcinoma, oncocytic papillary renal cell carcinoma, follicular renal carcinoma and leiomyomatous renal cell carcinoma.
  • It behooves the surgical pathologist to not only be capable of diagnosing the common forms of renal cancer, but also to be aware of the rare types of renal carcinoma, many of which have emerged in recent years.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19494850.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  •  go-up   go-down


61. Flores MR, Argueta VL, Ruiz MR, Florian RE: Mucinous cystadenocarcinoma of the renal pelvis: a case report and clues to histogenesis. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenocarcinoma of the renal pelvis: a case report and clues to histogenesis.
  • We present a case of mucinous cystadenocarcinoma of the renal pelvis associated with a collecting duct carcinoma in a 58-year-old woman with diabetes.
  • Even though several theories about the aetiology of mucinous cystadenocarcinoma of the renal pelvis have been proposed, its origin remains unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2004 Nov;11(11):1016-8 [15509208.001]
  • [Cites] Int J Urol. 2005 May;12(5):493-6 [15948751.001]
  • [Cites] Adv Anat Pathol. 2008 May;15(3):127-39 [18434765.001]
  • [Cites] Urol Int. 1997;58(2):121-3 [9096276.001]
  • [Cites] Gan No Rinsho. 1989 Mar;35(4):499-504 [2654443.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):954-5 [3840007.001]
  • [Cites] Arch Pathol Lab Med. 1993 Nov;117(11):1156-60 [8239939.001]
  • (PMID = 21686862.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029164
  •  go-up   go-down


62. Horcajada P, Serre C, Maurin G, Ramsahye NA, Balas F, Vallet-Regí M, Sebban M, Taulelle F, Férey G: Flexible porous metal-organic frameworks for a controlled drug delivery. J Am Chem Soc; 2008 May 28;130(21):6774-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Flexible nanoporous chromium or iron terephtalates (BDC) MIL-53(Cr, Fe) or M(OH)[BDC] have been used as matrices for the adsorption and in vitro drug delivery of Ibuprofen (or alpha- p-isobutylphenylpropionic acid).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHROMIUM COMPOUNDS .
  • Hazardous Substances Data Bank. TEREPHTHALIC ACID .
  • Hazardous Substances Data Bank. IBUPROFEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454528.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromium Compounds; 0 / Delayed-Action Preparations; 0 / Ferric Compounds; 0 / Phthalic Acids; 6S7NKZ40BQ / terephthalic acid; WK2XYI10QM / Ibuprofen
  •  go-up   go-down


63. Zhai H: (1H-1,3-Benzimidazole-5,6-dicarboxylic acid)(5-carboxyl-ato-1H-1,3-benzimidazole-6-carboxylic acid)silver(I) monohydrate. Acta Crystallogr Sect E Struct Rep Online; 2009;65(Pt 11):m1483
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 5-carboxyl-ato-1H-1,3-benzimidazole-6-carboxylic acid (bdc), and one solvent water mol-ecule, the latter being disordered over three sites with site occupancy factors of 0.375 (× 2) and 0.25.
  • The Ag atom is in a virtually linear geometry defined by two N atoms derived from the bdc and bdcH ligands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Crystallogr C. 2007 May;63(Pt 5):m216-9 [17478904.001]
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • [Cites] Acta Crystallogr Sect E Struct Rep Online. 2008;64(Pt 7):m928 [21202783.001]
  • [Cites] Acta Crystallogr Sect E Struct Rep Online. 2009;65(Pt 7):m775 [21582705.001]
  • (PMID = 21578205.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2971189
  •  go-up   go-down


64. Moses KA, Decaro JJ, Osunkoya AO, Issa MM: Tubulocystic carcinoma of the kidney: a case report of natural history and long-term follow-up. ScientificWorldJournal; 2010;10:586-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulocystic carcinoma of the kidney: a case report of natural history and long-term follow-up.
  • Tubulocystic carcinoma (TC) is a rare primary renal tumor that has been recently described in the pathology literature.
  • Formerly termed low-grade collecting duct carcinoma, further molecular analysis has shown TC to be a distinct entity that is separate from the more aggressive collecting duct carcinoma.
  • [MeSH-major] Kidney Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364244.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Kals J, Kampus P, Kals M, Zilmer K, Kullisaar T, Teesalu R, Pulges A, Zilmer M: Impact of oxidative stress on arterial elasticity in patients with atherosclerosis. Am J Hypertens; 2006 Sep;19(9):902-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The elasticity indices of the arteries were derived from PWA based on the modified Windkessel model and the OxS status was measured using urinary 8-iso-prostaglandin F2alpha (F2-IsoPs) and plasma baseline diene conjugates of low-density lipoproteins (LDL-BDC).
  • RESULTS: Patients with PAD showed significantly reduced C1 and C2 and increased values of F2-IsoPs and LDL-BDC.

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16942931.001).
  • [ISSN] 0895-7061
  • [Journal-full-title] American journal of hypertension
  • [ISO-abbreviation] Am. J. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Glucose; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Triglycerides; 27415-26-5 / 8-epi-prostaglandin F2alpha; AYI8EX34EU / Creatinine; B7IN85G1HY / Dinoprost
  •  go-up   go-down


66. Luo G, Johnson S, Hsueh MM, Zheng J, Cai H, Xin B, Chong S, He K, Harper TW: In silico prediction of biliary excretion of drugs in rats based on physicochemical properties. Drug Metab Dispos; 2010 Mar;38(3):422-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The bile duct-cannulated (BDC) rat model is commonly used to determine the percentage of dose excreted as intact parent into bile.
  • However, a study using BDC rats is time-consuming and cost-ineffective.
  • The compounds were given intravenously at <10 mg/kg to BDC rats, and bile was collected for at least 8 h after dosing.
  • In addition, biliary excretion was also highly corrected with the presence of a carboxylic acid moiety in the test compounds (r = 0.87).
  • [MeSH-minor] Animals. Bile Ducts. Carboxylic Acids / analysis. Carboxylic Acids / chemistry. Carboxylic Acids / pharmacokinetics. Catheters, Indwelling. Computational Biology. Least-Squares Analysis. Male. Models, Biological. Physicochemical Phenomena. Rats. Rats, Sprague-Dawley. Solubility. Surface Properties

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995888.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carboxylic Acids; 0 / Drugs, Investigational
  •  go-up   go-down


67. You J, Ming Y, Shi Y, Zhao X, Suo Y, Wang H, Li Y, Sun J: Development of a sensitive fluorescent derivatization reagent 1,2-benzo-3,4-dihydrocarbazole-9-ethyl chloroformate (BCEOC) and its application for determination of amino acids from seeds and bryophyte plants using high-performance liquid chromatography with fluorescence detection and identification with electrospray ionization mass spectrometry. Talanta; 2005 Dec 15;68(2):448-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a sensitive fluorescent derivatization reagent 1,2-benzo-3,4-dihydrocarbazole-9-ethyl chloroformate (BCEOC) and its application for determination of amino acids from seeds and bryophyte plants using high-performance liquid chromatography with fluorescence detection and identification with electrospray ionization mass spectrometry.
  • Derivatives exhibit strong fluorescence and extracted derivatization solution with n-hexane/ethyl acetate (10:1, v/v) allows for the direct injection with no significant interference from the major fluorescent reagent degradation by-products, such as 1,2-benzo-3,4-dihydrocarbazole-9-ethanol (BDC-OH) (a major by-product), mono-1,2-benzo-3,4-dihydrocarbazole-9-ethyl carbonate (BCEOC-OH) and bis-(1,2-benzo-3,4-dihydrocarbazole-9-ethyl) carbonate (BCEOC)(2).
  • Therefore, the facile BCEOC derivatization coupled with mass spectrometry allowed the development of a highly sensitive and specific method for the quantitative analysis of trace levels of amino acids and peptides from biological and natural environmental samples.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18970343.001).
  • [ISSN] 1873-3573
  • [Journal-full-title] Talanta
  • [ISO-abbreviation] Talanta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. David KA, Milowsky MI, Nanus DM: Chemotherapy for non-clear-cell renal cell carcinoma. Clin Genitourin Cancer; 2006 Mar;4(4):263-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for non-clear-cell renal cell carcinoma.
  • Clear-cell carcinoma is the most common histopathologic subtype of kidney tumors.
  • Consequently, clinical trials for advanced-stage kidney cancer have focused on patients with clear-cell carcinoma and not on the less common subtypes, including papillary, chromophobe, collecting-duct carcinoma, and sarcomatoid-variant tumors.
  • Whereas immunotherapy has constituted the standard treatment for patients with clear-cell renal cell carcinoma (RCC), it does not appear to have activity in the management of patients with other histologic subtypes.
  • In this article, we will review the literature and present our experience with the use of chemotherapy in patients with non-clear-cell kidney cancer by histologic subtype.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology


69. Habib HA, Hoffmann A, Höppe HA, Janiak C: Crystal structures and solid-state CPMAS 13C NMR correlations in luminescent zinc(II) and cadmium(II) mixed-ligand coordination polymers constructed from 1,2-bis(1,2,4-triazol-4-yl)ethane and benzenedicarboxylate. Dalton Trans; 2009 Mar 14;(10):1742-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hydrothermal reaction of M(NO(3))(2).4H(2)O (M = Zn and Cd) with benzene-1,4-dicarboxylic acid (H(2)bdc) or benzene-1,3-dicarboxylic acid (H(2)ip) and 1,2-bis(1,2,4-triazol-4-yl)ethane (btre) produced the mixed-ligand coordination polymers (MOFs) {[Zn(2)(micro(2)-bdc)(2)(micro(4)-btre)]} (), {[Cd(2)(micro(4)-bdc)(micro(4)-btre)(2)](NO(3))(2).H(2)O} and {[Zn(2)(micro(3)-ip)(2)(micro(2)-btre)(H(2)O)(2)].2H(2)O} ().
  • The CPMAS (13)C NMR spectra picture the symmetry-independent (unique) C atoms and the bdc/ip-to-btre ligand ratio in agreement with the crystal structures.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240907.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Mabrut JY, Partensky C, Gouillat C, Baulieux J, Ducerf C, Kestens PJ, Boillot O, de la Roche E, Gigot JF: Cystic involvement of the roof of the main biliary convergence in adult patients with congenital bile duct cysts: a difficult surgical challenge. Surgery; 2007 Feb;141(2):187-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic involvement of the roof of the main biliary convergence in adult patients with congenital bile duct cysts: a difficult surgical challenge.
  • BACKGROUND: Complete cyst excision of the extrahepatic disease component with biliary reconstruction on proximal healthy bile ducts is considered to be the treatment of choice in patients with congenital bile duct cysts (BDC).
  • METHODS: A retrospective multicenter study was conducted in 4 European surgical centers concerning their experience with adult patients suffering from type I and IV BDC according to the Todani classification.
  • Clinical presentation, operative management, and postoperative outcome were compared between patients with or without proximal extrahepatic cystic disease that involved at least the roof of the MBC (defined as being BDC with MBC involvement subgroup).
  • RESULTS: From an overall series of 49 adult patients suffering from type I or IV BDC according to the Todani classification, 7 patients had BDC with MBC involvement (14%).
  • Patient age, clinical presentation, duration of symptoms, associated major coexistent hepatobiliary and pancreatic diseases, and synchronous cancer were not significantly different in these patients compared with a control group of 42 adult patients with BDC without MBC involvement.
  • Incomplete proximal cyst excision rate was 86% in the cases of BDC with MBC involvement.
  • Early and late postoperative results were similar in BDC with MBC involvement and in the control group of adult patients, but the incidence of subsequent cancer was significantly higher in the BDC with MBC involvement group (29% vs 0%; P < .02).
  • CONCLUSION: BDC that involves the roof of the MBC is a real surgical challenge to obtain complete proximal cystic disease excision.
  • As suggested in this small study, primary incomplete excision of this particular form of BDC might expose the patient to the risk of subsequent cancer, a feature that must be confirmed in larger series.
  • [MeSH-major] Bile Ducts, Extrahepatic / pathology. Bile Ducts, Extrahepatic / surgery. Choledochal Cyst / pathology. Choledochal Cyst / surgery

  • Genetic Alliance. consumer health - Bile Duct Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263975.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


71. Liu XG, Huang J, Bao SS, Li YZ, Zheng LM: Homochiral zinc phosphonates with layered and open framework structures using polycarboxylate as second linkers. Dalton Trans; 2009 Nov 28;(44):9837-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reactions of zinc sulfate and (R)- or (S)-(1-phenylethylamino)methylphosphonic acid (pempH(2)) in the presence of 1,4-benzenedicarboxylic acid (H(2)bdc) result in homochiral enantiomers (R)- and (S)-[Zn(4)(pempH)(4)(bdc)(2)].2H(2)O ().
  • When H(2)bdc is replaced by 1,2,4,5-benzenetetracarboxylic acid (H(4)btec), enantiomers (R)- and (S)-[Zn(3)(pempH)(2)(btec)(H(2)O)(2)].H(2)O () are obtained.
  • Compounds have a layer structure in which the chiral inorganic double chains, made up of corner-sharing {ZnO(4)} and {PO(3)C} tetrahedra, are connected by bdc(2-).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885531.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T: Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol; 2008 Feb;15(2):590-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus.
  • BACKGROUND: Clinically hepatobiliary resection is indicated for both hilar bile duct cancer (BDC) and intrahepatic cholangiocarcinoma involving the hepatic hilus (CCC).
  • The aim of this study was to compare the long-term outcome of BDC and CCC.
  • RESULTS: The overall 3-year survival rate, 5-year survival rate, and median survival time for BDC patients were 48.4%, 38.4 %, and 33.7 months, respectively, and 35.8%, 24.5 %, and 22.7 months, respectively, in CCC patients (P = .033).
  • On multivariate analysis, three independent factors were related to longer survival in BDC patients: achieved in curative resection with cancer free margin (R0) (P = .024, odds ratio 1.862), well differentiated or papillary adenocarcinoma (P = .011, odds ratio 2.135), and absence of lymph node metastasis (P < .001, odds ratio 3.314).
  • Five factors were related to longer survival in CCC patients: absence of intrahepatic daughter nodules (P < .001, odds ratio 2.318), CEA level </=2.9 ng/mL (P = .005, odds ratio 2.606), no red blood cell transfusion requirement (P = .016, odds ratio 2.614), absence or slight degree of lymphatic system invasion (P < .001, odds ratio 4.577), and negative margin of the proximal bile duct (P = .003, odds ratio 7.398).
  • CONCLUSIONS: BDC and CCC appear to have different prognoses after hepatobiliary resection.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057991.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Tonkin DR, Haskins K: Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner. Eur J Immunol; 2009 May;39(5):1313-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner.
  • Treg can suppress autoimmune diseases such as type 1 diabetes, but their in vivo activity during suppression remains poorly characterized.
  • In type 1 diabetes, Treg activity has been demonstrated in the pancreatic lymph node, but little has been studied in the pancreas, the site of autoimmune islet destruction.
  • In this study we induced islet-specific Treg from the BDC-6.9 TCR transgenic mouse by activation of T cells in the presence of TGF-beta.
  • These Treg can suppress spontaneous diabetes as well as transfer of diabetes into NOD.scid mice by diabetic NOD spleen cells or activated BDC-2.5 TCR transgenic Th1 effector T cells.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Immunol. 2004 Sep;16(9):1241-9 [15249539.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5213-21 [15100259.001]
  • [Cites] Cell. 1993 Sep 24;74(6):1089-100 [8402882.001]
  • [Cites] J Exp Med. 1994 Sep 1;180(3):995-1004 [8064245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):213-8 [8990188.001]
  • [Cites] Autoimmunity. 1998;27(2):109-22 [9583742.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24 [15623559.001]
  • [Cites] J Immunol. 2005 Feb 15;174(4):1783-6 [15699103.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):737-46 [15753207.001]
  • [Cites] Diabetes. 2005 May;54(5):1415-22 [15855328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11817-22 [16087867.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4283-91 [16177068.001]
  • [Cites] Eur J Immunol. 2005 Oct;35(10):2886-95 [16180248.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7738-45 [16301684.001]
  • [Cites] Nat Immunol. 2006 Jan;7(1):83-92 [16311599.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):4730-9 [16585566.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1360-70 [16670772.001]
  • [Cites] Immunol Rev. 2006 Aug;212:185-202 [16903915.001]
  • [Cites] Nature. 2006 Aug 31;442(7106):997-1002 [16921386.001]
  • [Cites] Immunity. 2006 Sep;25(3):441-54 [16973387.001]
  • [Cites] J Biol Chem. 2006 Dec 15;281(50):38376-84 [17056601.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):191-201 [17210729.001]
  • [Cites] J Immunol. 2007 Nov 1;179(9):5760-7 [17947648.001]
  • [Cites] Nat Immunol. 2007 Dec;8(12):1353-62 [17982458.001]
  • [Cites] Nature. 2007 Nov 22;450(7169):566-9 [18033300.001]
  • [Cites] J Exp Med. 2008 Sep 1;205(9):1975-81 [18710931.001]
  • [Cites] J Immunol. 2008 Oct 1;181(7):4516-22 [18802054.001]
  • [Cites] Diabetes. 2008 Oct;57(10):2684-92 [18689691.001]
  • [Cites] J Exp Med. 2004 Jun 7;199(11):1455-65 [15184499.001]
  • [Cites] Immunity. 2000 Apr;12(4):431-40 [10795741.001]
  • [Cites] J Immunol. 2001 Jan 15;166(2):1352-9 [11145720.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2495-504 [11160310.001]
  • [Cites] Nat Immunol. 2001 May;2(5):397-402 [11323692.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] Immunol Rev. 2001 Aug;182:58-67 [11722623.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):6159-64 [12055228.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):237-46 [12119348.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):255-60 [12119350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12287-92 [12221281.001]
  • [Cites] Nat Med. 2003 Sep;9(9):1202-8 [12937416.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10878-83 [12949259.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] Diabetes. 2004 Apr;53(4):978-88 [15047613.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5149-53 [15100250.001]
  • [Cites] Immunity. 2004 Oct;21(4):589-601 [15485635.001]
  • (PMID = 19404982.001).
  • [ISSN] 1521-4141
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK050561-11; United States / NIDDK NIH HHS / DK / DK050561-11; United States / NIDDK NIH HHS / DK / R56 DK050561; United States / NIDDK NIH HHS / DK / R01 DK050561; United States / NIDDK NIH HHS / DK / R01 DK50561
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ NIHMS138319; NLM/ PMC2939012
  •  go-up   go-down


74. Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol; 2006 Oct;37(10):1268-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vitamin D3 receptor in kidney tumors.
  • The kidney is not only a primary vitamin D target organ but also is a key site of vitamin D metabolism.
  • Our preliminary immunohistochemical study showed that vitamin D receptor (VDR) was highly expressed in renal distal tubules and collecting ducts, whereas the renal proximal tubules and glomeruli did not express VDR.
  • These observations led us to study the expression of VDR in various kidney tumors to determine the possible diagnostic utility of VDR.
  • Paraffin tissue microarray (TMA) blocks were constructed containing core cylinders from clear cell (52), papillary (35), chromophobe (20), sarcomatoid (20), and metastatic (59) renal cell carcinomas (RCCs).
  • In addition, 30 clear cell RCCs and 3 collecting duct carcinomas were also studied using conventional sections.
  • Vitamin D receptor was strongly positive in collecting duct carcinomas (100% [3/3], cytoplasmic), papillary RCCs (94% [33/35], cytoplasmic), chromophobe RCCs (85% [17/20], membranous), and oncocytomas (90% [18/20], cytoplasmic with perinuclear accentuation).
  • Vitamin D receptor was weakly positive in sarcomatoid variant RCCs (88% [14/16]) regardless of the type of associated original RCC.
  • Overall, VDR is a discriminative marker for renal cell tumors.
  • The preferential expression of VDR in chromophobe RCCs, oncocytomas, and collecting duct carcinomas is in agreement with the concept that these tumors differentiate toward epithelium lining the distal convoluted tubules and collecting ducts.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Receptors, Calcitriol / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Gene Expression. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949927.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Calcitriol
  •  go-up   go-down


75. Mahata P, Ramya KV, Natarajan S: Reversible water intercalation accompanied by coordination and color changes in a layered metal-organic framework. Inorg Chem; 2009 Jun 1;48(11):4942-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new two-dimensional 3d-4f mixed-metal mixed dicarboxylate (homocyclic and heterocyclic) of the formula [Gd(2)(H(2)O)(2)Ni(H(2)O)(2)(1,2-bdc)(2)(2,5-pydc)(2)].8H(2)O (1; 1,2-H(2)bdc = 1,2-benzenedicarboxylic acid and 2,5-H(2)pydc = 2,5-pyridinedicarboxylic acid) has been prepared by employing the hydrothermal method.
  • The structure has infinite one-dimensional -Gd-O-Gd- chains formed by the edge-shared GdO(9) polyhedral units, resulting exclusively from the connectivity between the Gd(3+) ions and the 1,2-bdc units.
  • A one-dimensional water ladder structure, formed by the extraframework water molecules, occupies the hydrophilic region while the benzene ring of 1,2-bdc occupies the hydrophobic region.
  • To the best of our knowledge, the present compound represents the first example of a 3d-4f mixed-metal carboxylate in which two different aromatic dicarboxylate anions act as the linkers.

  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374369.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 059QF0KO0R / Water; 7OV03QG267 / Nickel; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


76. Ockrim J, Tsiriopoulos I, Rees H, Mendoza N, Christmas TJ: Collecting duct carcinoma of the renal medulla presenting with paraplegia. Int Urol Nephrol; 2005;37(3):465-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma of the renal medulla presenting with paraplegia.
  • We report an interesting case of a patient with collecting duct carcinoma arising from the left kidney who presented with paraplegia secondary to metastases.
  • The diagnosis was based on CT and histology.
  • To our knowledge this is the first case of collecting duct carcinoma to present with paraplegia.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / diagnosis. Kidney Medulla. Kidney Neoplasms / complications. Kidney Neoplasms / diagnosis. Paraplegia / etiology


77. Uemura K, Yamasaki Y, Onishi F, Kita H, Ebihara M: Two-step adsorption on jungle-gym-type porous coordination polymers: dependence on hydrogen-bonding capability of adsorbates, ligand-substituent effect, and temperature. Inorg Chem; 2010 Nov 1;49(21):10133-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-step adsorption on jungle-gym-type porous coordination polymers: dependence on hydrogen-bonding capability of adsorbates, ligand-substituent effect, and temperature.
  • A preliminary study of isopropanol (IPA) adsorption/desorption isotherms on a jungle-gym-type porous coordination polymer, [Zn(2)(bdc)(2)(dabco)](n) (1, H(2)bdc = 1,4-benzenedicarboxylic acid, dabco =1,4-diazabicyclo[2.2.2]octane), showed unambiguous two-step profiles via a highly shrunk intermediate framework.
  • The results of adsorption measurements on 1, using probing gas molecules of alcohol (MeOH and EtOH) for the size effect and Me(2)CO for the influence of hydrogen bonding, show that alcohol adsorption isotherms are gradual two-step profiles, whereas the Me(2)CO isotherm is a typical type-I isotherm, indicating that a two-step adsorption/desorption is involved with hydrogen bonds.
  • To further clarify these characteristic adsorption/desorption behaviors, selecting nitroterephthalate (bdc-NO(2)), bromoterephthalate (bdc-Br), and 2,5-dichloroterephthalate (bdc-Cl(2)) as substituted dicarboxylate ligands, isomorphous jungle-gym-type porous coordination polymers, {[Zn(2)(bdc-NO(2))(2)(dabco)]·solvents}(n) (2 ⊃ solvents), {[Zn(2)(bdc-Br)(2)(dabco)]·solvents}(n) (3 ⊃ solvents), and {[Zn(2)(bdc-Cl(2))(2)(dabco)]·solvents}(n) (4 ⊃ solvents), were synthesized and characterized by single-crystal X-ray analyses.
  • Thermal gravimetry, X-ray powder diffraction, and N(2) adsorption at 77 K measurements reveal that [Zn(2)(bdc-NO(2))(2)(dabco)](n) (2), [Zn(2)(bdc-Br)(2)(dabco)](n) (3), and [Zn(2)(bdc-Cl(2))(2)(dabco)](n) (4) maintain their frameworks without guest molecules with Brunauer-Emmett-Teller (BET) surface areas of 1568 (2), 1292 (3), and 1216 (4) m(2) g(-1).

  • Hazardous Substances Data Bank. 1,4-DIAZABICYCLO(2.2.2)OCTANE .
  • Hazardous Substances Data Bank. ISOPROPANOL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20929220.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1,4-benzenedicarboxylate; 0 / Ligands; 0 / Organometallic Compounds; 0 / Phthalic Acids; 0 / Piperazines; 0 / Polymers; J41CSQ7QDS / Zinc; ND2M416302 / 2-Propanol; X8M57R0JS5 / triethylenediamine
  •  go-up   go-down


78. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJ, Schalken JA, van den Brandt PA, Oosterwijk E: Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer; 2005;5:57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.
  • BACKGROUND: Biallelic von Hippel-Lindau (VHL) gene defects, a rate-limiting event in the carcinogenesis, occur in approximately 75% of sporadic clear-cell Renal Cell Carcinoma (RCC).
  • METHODS: Cases were identified within the Netherlands cohort study on diet and cancer, which includes 120,852 men and women.
  • In other histological types, we observed 8 mutations in 7 out of 48 patients (15%), 1 mutation in 1 of 6 oncocytoma, 3 mutations in 2 of 7 chromophobe RCC, 2 mutations in 2 of 30 papillary RCC, no mutations in 1 collecting duct carcinoma and 2 mutations in 2 of 4 unclassified RCC.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Mutation. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):58-68 [11921283.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):713-7 [11792959.001]
  • [Cites] J Surg Oncol. 2002 May;80(1):52-60 [11967908.001]
  • [Cites] Am J Nephrol. 2004 Jan-Feb;24(1):1-13 [14654728.001]
  • [Cites] Toxicol Lett. 2004 Jun 15;151(1):301-10 [15177666.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S [15448019.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Nature. 1987 Jun 25-Jul 1;327(6124):721-4 [2885753.001]
  • [Cites] J Clin Epidemiol. 1990;43(3):285-95 [2313318.001]
  • [Cites] Int J Epidemiol. 1990 Sep;19(3):553-8 [2262247.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4 [7937876.001]
  • [Cites] Hum Mol Genet. 1994 Dec;3(12):2169-73 [7881415.001]
  • [Cites] Int J Cancer. 1995 Nov 27;63(5):660-4 [7591282.001]
  • [Cites] Biochim Biophys Acta. 1996 Mar 18;1242(3):201-10 [8603073.001]
  • [Cites] Mod Pathol. 1996 Aug;9(8):838-42 [8871925.001]
  • [Cites] Oncology. 1997 May-Jun;54(3):252-7 [9143408.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8817-22 [9671762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11661-6 [9751722.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 18;90(22):1720-3 [9827526.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1529-35 [10102622.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):854-61 [10340905.001]
  • [Cites] Hum Mutat. 1999;13(6):464-75 [10408776.001]
  • [Cites] Cancer Lett. 1999 Jul 1;141(1-2):1-8 [10454237.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1999 May;8(3):325-31 [10456263.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1467-71 [10550302.001]
  • [Cites] Hum Mutat. 2000;15(1):86-94 [10612827.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1942-8 [10766184.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):115-23 [10768591.001]
  • [Cites] Pharmacogenetics. 2001 Aug;11(6):521-35 [11505222.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5393-400 [11536052.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):809-15 [12016154.001]
  • (PMID = 15932632.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / DNA Primers; 9007-49-2 / DNA; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ PMC1177929
  •  go-up   go-down


79. Felger JC, Abe T, Kaunzner UW, Gottfried-Blackmore A, Gal-Toth J, McEwen BS, Iadecola C, Bulloch K: Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain Behav Immun; 2010 Jul;24(5):724-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One cell type involved in both innate and adaptive immunity is the dendritic cell (DC).
  • A DC population residing in the healthy brain (bDC) was identified using a transgenic mouse expressing enhanced yellow fluorescent protein (EYFP) under the promoter for the DC marker, CD11c (CD11c/EYFP Tg).
  • To determine if bDC are involved in the immune response to cerebral ischemia, transient (40 min) middle cerebral artery occlusion (MCAO) followed by 6, 24, or 72 h reperfusion was conducted in CD11c/EYFP Tg mice.
  • To distinguish resident bDC from the infiltrating peripheral DC, radiation chimeras [1. wild type (WT) hosts restored with CD11c/EYFP Tg bone marrow (BM) or 2.
  • These data confirmed that DC populating the core of the infarct at 72 h were of peripheral origin, whereas those in the border region were comprised primarily of resident bDC.
  • Compared to microglia, bDC displayed increased major histocompatibility class II (MHC II) and co-stimulatory molecules following MCAO-reperfusion.
  • High levels of MHC II and the co-stimulatory molecule CD80 on bDC at 72 h corresponded to peak lymphocyte infiltration, and suggested a functional interaction between these two immune cell populations.

  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Trends Immunol. 2003 Jun;24(6):314-9 [12810107.001]
  • [Cites] Eur J Immunol. 2002 Oct;32(10):2888-96 [12355442.001]
  • [Cites] Stroke. 2003 Jul;34(7):1790-5 [12805500.001]
  • [Cites] J Neurosci. 2003 Aug 27;23(21):7922-30 [12944523.001]
  • [Cites] J Exp Med. 2003 Sep 1;198(5):725-36 [12939340.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6549-55 [14662856.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):2778-84 [14978077.001]
  • [Cites] Stroke. 1994 Apr;25(4):869-75; discussion 875-6 [8160235.001]
  • [Cites] J Cereb Blood Flow Metab. 1994 Jul;14(4):697-8 [7516936.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):241-8 [8546211.001]
  • [Cites] Blood. 1997 Aug 1;90(3):986-93 [9242527.001]
  • [Cites] Adv Exp Med Biol. 1997;417:55-7 [9286337.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10873-8 [9380727.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1243-50 [15543150.001]
  • [Cites] J Neurosci. 2005 Mar 9;25(10):2504-12 [15758158.001]
  • [Cites] Hepatology. 2006 Jan;43(1):154-62 [16374849.001]
  • [Cites] Nat Med. 2006 Feb;12(2):225-9 [16432513.001]
  • [Cites] J Cereb Blood Flow Metab. 2006 May;26(5):654-65 [16121126.001]
  • [Cites] Circulation. 2006 May 2;113(17):2105-12 [16636173.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6523-31 [16709809.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11784-9 [16864778.001]
  • [Cites] Stroke. 2007 Feb;38(2 Suppl):783-8 [17261738.001]
  • [Cites] J Neuroimmunol. 2007 Mar;184(1-2):53-68 [17188755.001]
  • [Cites] Mol Cell Neurosci. 2007 Jul;35(3):490-500 [17560122.001]
  • [Cites] J Neurosci. 2007 Jul 4;27(27):7083-93 [17611261.001]
  • [Cites] Neurosci Lett. 2007 Sep 25;425(2):110-3 [17868996.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):419-26 [17898760.001]
  • [Cites] J Neurosci. 2008 Feb 13;28(7):1649-58 [18272685.001]
  • [Cites] J Comp Neurol. 2008 Jun 10;508(5):687-710 [18386786.001]
  • [Cites] Neuropharmacology. 2008 Sep;55(3):310-8 [18308346.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17913-8 [18997009.001]
  • [Cites] Nat Med. 2009 Feb;15(2):192-9 [19169263.001]
  • [Cites] Nat Med. 2009 Feb;15(2):138-9 [19197285.001]
  • [Cites] Neuroscience. 2009 Feb 6;158(3):1098-111 [18597949.001]
  • [Cites] Neuroscience. 2009 Feb 6;158(3):1049-61 [18789376.001]
  • [Cites] J Neurosci. 2009 Feb 18;29(7):2089-102 [19228962.001]
  • [Cites] Stroke. 2009 May;40(5):1849-57 [19265055.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2717-26 [11160337.001]
  • [Cites] J Neuroimmunol. 2001 May 1;116(1):5-14 [11311324.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6295-300 [11371643.001]
  • [Cites] Stroke. 2001 May;32(5):1208-15 [11340235.001]
  • [Cites] Nat Med. 2001 Dec;7(12):1356-61 [11726978.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):87-90 [11753368.001]
  • [Cites] Brain Res. 2002 Apr 5;932(1-2):110-9 [11911867.001]
  • [Cites] Stroke. 2002 Apr;33(4):1129-34 [11935071.001]
  • [Cites] J Neuroimmunol. 2002 Aug;129(1-2):125-32 [12161028.001]
  • [Cites] Stroke. 2003 Jul;34(7):1704-9 [12805489.001]
  • (PMID = 19914372.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG016765-100001; United States / NINDS NIH HHS / NS / R01 NS034179; United States / NIA NIH HHS / AG / P01 AG016765-100001; United States / NINDS NIH HHS / NS / R01 NS035806; United States / NINDS NIH HHS / NS / NS35806; United States / NINDS NIH HHS / NS / R37 NS034179; United States / NIA NIH HHS / AG / P01 AG016765; United States / NINDS NIH HHS / NS / NS34179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD11c
  • [Other-IDs] NLM/ NIHMS165073; NLM/ PMC2885548
  •  go-up   go-down


80. Vougo-Zanda M, Huang J, Anokhina E, Wang X, Jacobson AJ: Tossing and turning: guests in the flexible frameworks of metal(III) dicarboxylates. Inorg Chem; 2008 Dec 15;47(24):11535-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The structures of 2 and 3 have the same topological framework as the previously reported aluminum 1,4-benzenedicarboxylate (BDC), Al(OH)(C(8)H(4)O(4)).0.7C(8)H(6)O(4) (1).
  • The frameworks are built by interconnecting M-OH-M chains (M = Al, Ga) with BDC anions to form large diamond-shaped one-dimensional channels filled with additional H(2)BDC guest molecules occupying disordered positions in the channels.
  • Upon removal of H(2)BDC, other guest molecules such as H(2)O and pyridine can be inserted.
  • In this work, we present a study of the intercalation of aromatic guests (BDC and pyridine) into frameworks of 1-3 by liquid and vapor diffusion into the empty channels of 1 and by single-crystal-to-single-crystal solvothermal guest exchange for 2 and 3.
  • In the case of Al(OH)BDC and Ga(OH,F)BDC, two interconvertible, guest-concentration-dependent phases with different orientations of the pyridine guests have been observed, while only one pyridine orientation is found in Ga(OH)BDC.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433098.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. He Q, Huang BJ: Poly[di-μ(4)-benzene-1,4-dicarboxyl-ato-μ(6)-succinato-diholmium(III)]. Acta Crystallogr Sect E Struct Rep Online; 2007;64(Pt 1):m237
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly[di-μ(4)-benzene-1,4-dicarboxyl-ato-μ(6)-succinato-diholmium(III)].
  • The title compound, [Ho(2)(C(4)H(4)O(4))(C(8)H(4)O(4))(2)](n), was synthesized hydro-thermally.
  • The Ho atom is coordinated by four O atoms from four benzene-1,4-dicarboxyl-ate (BDC) anions and four O atoms from three succinate anions, in a distorted square-anti-prismatic coordination geometry.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21200579.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2915157
  •  go-up   go-down


82. Staehler M, Schöppler G, Haseke N, Stadler T, Karl A, Siebels M, Ihrler S, Stief CG: Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib. Clin Genitourin Cancer; 2009 Jan;7(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
  • BACKGROUND: Carcinoma of the collecting ducts (CDC) of Bellini of the kidney is very rare but is among the most aggressive urologic entities.
  • Eight weeks later, the patients died, with a survival of 8 months from initial diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Kidney Tubules, Collecting / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213670.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


83. Ozgiray E, Cağli S, Zileli M, Cinar C, Oran I: Occlusion of the abdominal aorta by balloon dilation catheter assisting surgical excision of a sacrum chordoma: case report. Turk Neurosurg; 2009 Jul;19(3):265-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occlusion of the abdominal aorta by balloon dilation catheter assisting surgical excision of a sacrum chordoma: case report.
  • Prior to the surgery, a balloon dilation catheter (BDC) was placed in the distal abdominal aorta via the femoral artery.
  • Just after the skin incision, the BDC was inflated with contrast medium and total occlusion of the aorta was achieved.

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621292.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


84. Wang XL, Qin C, Wang EB, Su ZM: Metal nuclearity modulated four-, six-, and eight-connected entangled frameworks based on mono-, bi-, and trimetallic cores as nodes. Chemistry; 2006 Mar 20;12(10):2680-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the relationship between network connectivity and metal nuclearity, we designed and synthesized a series of three-dimensional (3D) entangled coordination frameworks based on different metal cores, namely [Zn(2)(bdc)(2)(L)(2)]2H(2)O (1), [Zn(bdc)(L)(0.5)] (2), [Zn(oba)(L)(0.5)] (3) and [Cd(3)(bdc)(3)(L)(2)(H(2)O)(2)] (4) by self-assembly of d(10) metal salts with the flexible long-chain ligand 1,4-bis(1,2,4-triazol-1-yl)butane (L), and with the rigid and nonrigid aromatic dicarboxylate ligands 1,4-benzenedicarboxylate (bdc) and 4,4'-oxybis(benzoate) (oba).
  • Compound 2 adopts a threefold interpenetrated alpha-polonium-type network that is built from bimetallic cores as six-connected vertices.
  • Compound 4, derived from a crosslinked fivefold interpenetrated diamond-like substructure, is an unusual example of a self-penetrating coordination framework displaying an unprecedented eight-connected 4(20)6(8) topology with trinuclear cadmium clusters as eight-connected nodes which, to our knowledge, not only defines a new topology for eight-connected coordination networks, but also represents the highest connected topology presently known for self-penetrating systems.
  • Detailed structural comparison of these complexes indicates that the increase in metal nuclearity induces the progressive increase in the connectivities of the ultimate nets: that is, the metal nuclearity plays a significant role in tuning the connectivity of a specific network.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16470773.001).
  • [ISSN] 0947-6539
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G: Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology; 2010 Apr;56(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.
  • AIMS: To study the relevance of periostin, known to be involved in epithelial-mesenchymal transition (EMT), in hepatocellular and bile duct cancer.
  • METHODS AND RESULTS: Immunohistochemical periostin expression was semiquantitatively analysed in normal liver tissue (n = 20), hepatocellular carcinoma (HCC; n = 91), liver-cell adenoma (n = 9), focal nodular hyperplasia (n = 13) and bile duct carcinomas (BDC; n = 116) using tissue microarrays.
  • Normal bile ducts, gallbladder epithelium and hepatocytes showed weak cytoplasmic periostin expression.
  • Strong stromal periostin expression was detected in 78/116 (67.2%) BDC and strong epithelial expression in 39/116 (33.6%) BDC. pT stage, differentiation grade and proliferation rate in primary BDC were independent of periostin expression.
  • CONCLUSIONS: The EMT protein periostin is expressed in the stroma and epithelium of a subset of BDC and HCC.
  • Epithelial periostin expression is a marker for malignant transformation of hepatocytes and a novel prognostic marker in BDC.
  • [MeSH-major] Adenoma / metabolism. Bile Duct Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Cell Adhesion Molecules / metabolism. Focal Nodular Hyperplasia / metabolism. Liver Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459570.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human
  •  go-up   go-down


86. Ansari J, Fatima A, Chaudhri S, Bhatt RI, Wallace M, James ND: Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie; 2009 Feb;32(1-2):44-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
  • BACKGROUND: Collecting duct carcinoma (CDC) is a rare and aggressive variant of renal cell carcinoma (RCC), which has poor response to cytokine therapy and chemotherapy.
  • CONCLUSIONS: This is the first reported case of a patient with CDC responding to sorafenib treatment.
  • [MeSH-major] Benzenesulfonates / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / drug therapy. Pyridines / administration & dosage

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 S. Karger AG, Basel.
  • (PMID = 19209019.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


87. Tanaka D, Higuchi M, Horike S, Matsuda R, Kinoshita Y, Yanai N, Kitagawa S: Storage and sorption properties of acetylene in jungle-gym-like open frameworks. Chem Asian J; 2008 Sep 1;3(8-9):1343-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The acetylene-sorption properties of six porous coordination polymers (PCPs), [M(2)(L)(2)(dabco)](n) (dabco=1,4-diazabicyclo[2.2.2]octane, M=Cu(2+) (1), Zn(2+) (2), L=1,4-benzenedicarboxylate (bdc; 1 a, 2 a), 1,4-naphthalenedicarboxylate (ndc; 1 b, 2 b), 9,10-anthracenedicarboxylate (adc; 1 c, 2 c)), were investigated.
  • The acetylene sorption isotherms of 1 and 2 measured at 195 K are of type I and show a steep increase at low relative pressures.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618609.001).
  • [ISSN] 1861-471X
  • [Journal-full-title] Chemistry, an Asian journal
  • [ISO-abbreviation] Chem Asian J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Algaba F, Arce Y, Trias I, Santaularia JM, Antonio Rosales A: [Usefulness of the present renal cell carcinoma classifications]. Actas Urol Esp; 2006 Apr;30(4):372-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of the present renal cell carcinoma classifications].
  • [Transliterated title] Aplicación clínica de las actuales clasificaciones del cáncer renal.
  • Differentiation of various entities in renal cancer has been comparatively fast, as the new genetic and molecular discoveries have confirmed the morphologic criteria of the different cell types, thus making it possible to open new therapeutic pathways.
  • Using the current WHO classification we recognize subtypes with excellent prognosis (Multilocular cystic renal carcinoma, Type I renal papillary carcinoma, Tubular and fusocellular mucinous carcinoma), other very aggressive ones (Bellini's collecting duct carcinoma, Medullary carcinoma), and also that the sarcomatoid transformation, even in small areas, impacts the prognosis negatively.
  • Childhood-characteristic renal carcinomas associated with chromosome translocations have been recognized (genetic fusion TFE3 or TFEB), as well as the family forms of renal carcinoma.
  • Regarding the UICC (International Union Against Cancer) classification, there are a series of aspects under argument (size, venous invasion, microvascular invasion, invasion of the adipous tissue of the renal sinus) that shall be discussed too, since it is possible that some modifications of the TNM might occur in the near future.
  • [MeSH-major] Carcinoma / classification. Kidney Neoplasms / classification
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / classification. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Cell Differentiation. Cell Nucleus / ultrastructure. Child. Chromosomes, Human / genetics. Chromosomes, Human / ultrastructure. Female. Humans. Kidney Tubules, Collecting / pathology. Male. Neoplasm Proteins / analysis. Neoplasms, Germ Cell and Embryonal / classification. Neoplasms, Germ Cell and Embryonal / pathology. Neoplastic Syndromes, Hereditary / genetics. Prognosis. Translocation, Genetic. World Health Organization

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838609.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 103
  •  go-up   go-down


89. Müller M, Zhang X, Wang Y, Fischer RA: Nanometer-sized titania hosted inside MOF-5. Chem Commun (Camb); 2009 Jan 7;(1):119-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nanoscale titania particles were synthesized inside the porous coordination polymer [Zn(4)O(bdc)(3)] (bdc = 1,4-benzene-dicarboxylate, MOF-5) by adsorption of titanium isopropoxide from the gas-phase and subsequent dry oxidation and annealing.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082018.001).
  • [ISSN] 1359-7345
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Xing XP, Wang XB, Wang LS: Photoelectron angular distribution and molecular structure in multiply charged anions. J Phys Chem A; 2009 Feb 12;113(6):945-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using photoelectron imaging, we observed the effects of ICR on photoelectron angular distributions (PAD) of the three isomers of benzene dicarboxylate dianions C6H4(CO2)2(2-) (o-, m- and p-BDC(2-)).
  • Photoelectrons were observed to peak along the laser polarization due to the ICR, but the anisotropy was the largest for p-BDC(2-), followed by the m- and o-isomer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19007194.001).
  • [ISSN] 1520-5215
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


91. Bharti R, Agarwal L: Topiramate and scars. Dermatol Online J; 2005;11(3):42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on that study, BDC Research Centre treated 91 patients with various scarring conditions including post acne, varicella, dermatitis scars, melasma, hypertrophic scars, and keloids.

  • MedlinePlus Health Information. consumer health - Scars.
  • Hazardous Substances Data Bank. TOPIRAMATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Dermatol Online J. 2003 Dec;9(5):3 [14996376.001]
  • (PMID = 16409938.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0H73WJJ391 / topiramate; 30237-26-4 / Fructose
  •  go-up   go-down


92. Molinié V, Balaton A, Rotman S, Mansouri D, De Pinieux I, Homsi T, Guillou L: Alpha-methyl CoA racemase expression in renal cell carcinomas. Hum Pathol; 2006 Jun;37(6):698-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methyl CoA racemase expression in renal cell carcinomas.
  • Alpha-methyl CoA racemase (AMACR), a new molecular marker for prostate cancer, has been recently reported to be one of the most highly expressed genes in papillary renal cell carcinomas (RCCs).
  • We tested the diagnostic usefulness of AMACR antibody in a series of 110 renal tumors: 53 papillary RCCs (33 type 1, 20 type 2); 25 conventional RCCs; 6 chromophobe RCCs; 9 oncocytomas; 5 mucinous tubular and spindle tumors; 2 urothelial carcinomas; 7 angiomyolipomas; and 2 Bellini carcinomas.
  • Both type 1 and type 2 papillary RCCs exhibited cytoplasmic immunoreactivity for AMACR, with diffuse strong granular staining in 96.4% (53/55) of tumors, without correlation with type or nuclear grade.
  • The 5 mucinous, tubular, and spindle cell carcinomas strongly expressed AMACR, and only 5 of 25 clear cell RCCs and 1 of 9 oncocytomas were focally reactive.
  • The remaining 6 chromophobe RCCs, 5 urothelial carcinomas, and Bellini duct carcinomas showed no immunoreactivity for AMACR.
  • Because high expression of AMACR is found in papillary RCCs (type 1 and 2) and in mucinous, tubular, and spindle cell carcinomas of the kidney, immunostaining for AMACR should be used in conjunction with other markers when histological typing of a renal tumor is difficult.
  • [MeSH-major] Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / enzymology. Kidney Neoplasms / pathology. Racemases and Epimerases / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / pathology. Adenoma, Oxyphilic / enzymology. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / pathology. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733210.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


93. Hao XR, Wang XL, Su ZM, Shao KZ, Zhao YH, Lan YQ, Fu YM: Two unprecedented porous anionic frameworks: organoammonium templating effects and structural diversification. Dalton Trans; 2009 Oct 28;(40):8562-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two unprecedented 3D porous anionic metal-organic frameworks, [Me2NH2]2[Cd2(bpdc)3].4dma 1 and [Me2NH2]2[Cd2(NH2bdc)3].4dma 2 (dma = N,N'-dimethylacetamide, bpdc = 4,4'-biphenyldicarboxylate, NH(2)bdc = 2-amino-1,4-benzenedicarboxylate) have been solvothermally synthesized with a dimethylammonium cations template.

  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19809732.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anions; 0 / Organometallic Compounds; 0 / Quaternary Ammonium Compounds; 00BH33GNGH / Cadmium
  •  go-up   go-down


94. García-Fadrique G, Ramírez-Backhaus M, Morales G, Pontones JL, Jiménez-Cruz JF: [Collecting duct carcinoma. Case report and a review of the literature]. Actas Urol Esp; 2010 Jul;34(7):639-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Collecting duct carcinoma. Case report and a review of the literature].
  • [Transliterated title] Carcinoma de los conductos colectores de bellini. Presentación de un caso y revisión de la literatura.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540884.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Spain
  •  go-up   go-down


95. Chu WH, Zhu W: Isolation of Bdellovibrio as biological therapeutic agents used for the treatment of Aeromonas hydrophila infection in fish. Zoonoses Public Health; 2010 Jun;57(4):258-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The optimum temperature for the growth of BdC-1 was between 15-37 degrees C and with optimal activity at temperatures of 25-30 degrees C.
  • The ability of BdC-1 to lyse A. hydrophila was similar in the pH range of 6.5 to 8.5.
  • Immersion of fish in water containing different concentrations of BdC-1 was used in protection against an experimental infection of A. hydrophila J-1.
  • Results show that the mortality of groups immersed with BdC-1 was lower than the group without BdC-1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486499.001).
  • [ISSN] 1863-2378
  • [Journal-full-title] Zoonoses and public health
  • [ISO-abbreviation] Zoonoses Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Kuroda N, Toi M, Hiroi M, Shuin T, Enzan H: Review of mucinous tubular and spindle-cell carcinoma of the kidney with a focus on clinical and pathobiological aspects. Histol Histopathol; 2005 01;20(1):221-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of mucinous tubular and spindle-cell carcinoma of the kidney with a focus on clinical and pathobiological aspects.
  • Recently, the characterization of mucinous tubular and spindle-cell carcinoma (MTSCC) has been established.
  • Some cases with MTSCC seem to show overlapping histology with low-grade collecting-duct carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / physiopathology. Kidney Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15578440.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


97. Staehler M, Haseke N, Schöppler G, Stadler T, Karl A, Siebels M, Ihrler S, Stief CG: Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. Eur J Med Res; 2008 Nov 24;13(11):531-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
  • INTRODUCTION: Carcinoma of the collecting ducts of Bellini of the kidney (CDC) is very rare but among the most aggressive urological entities.
  • 8 weeks later the patients died with a survival of 8 months from initial diagnosis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Renal Cell / drug therapy. Indoles / administration & dosage. Kidney Neoplasms / drug therapy. Pyrroles / administration & dosage
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Kidney Tubules, Collecting / pathology. Male. Middle Aged. Protein-Tyrosine Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073390.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Protein-Tyrosine Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


98. Maître B, Mangin PH, Eckly A, Heim V, Cazenave JP, Lanza F, Hanau D, Gachet C: Immature myeloid dendritic cells capture and remove activated platelets from preformed aggregates. J Thromb Haemost; 2010 Oct;8(10):2262-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This could be of importance for BDC maturation and antigen uptake during normal hemostasis or in the context of atherothrombosis at sites of reduced blood flow.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Society on Thrombosis and Haemostasis.
  • (PMID = 20633211.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Macrophage-1 Antigen; 0 / Membrane Glycoproteins; 0 / P-Selectin; 0 / P-selectin ligand protein; 0 / Platelet Glycoprotein GPIIb-IIIa Complex
  •  go-up   go-down


99. Garibay SJ, Wang Z, Cohen SM: Evaluation of heterogeneous metal-organic framework organocatalysts prepared by postsynthetic modification. Inorg Chem; 2010 Sep 6;49(17):8086-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A metal-organic framework (MOF) containing 2-amino-1,4-benzenedicarboxylate (NH(2)-BDC) as a building block is shown to undergo chemical modification with a set of cyclic anhydrides.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHANE .
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acc Chem Res. 2001 Apr;34(4):319-30 [11308306.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Sep 11;45(36):5974-8 [16897793.001]
  • [Cites] Chem Commun (Camb). 2008 Feb 21;(7):820-2 [18253515.001]
  • [Cites] Chem Commun (Camb). 2008 Mar 21;(11):1287-9 [18389109.001]
  • [Cites] J Am Chem Soc. 2010 Apr 7;132(13):4560-1 [20232871.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11623-7 [18711128.001]
  • [Cites] Inorg Chem. 2009 Aug 3;48(15):7341-9 [19580256.001]
  • [Cites] J Am Chem Soc. 2009 Oct 14;131(40):14261-3 [19807179.001]
  • [Cites] J Am Chem Soc. 2008 May 28;130(21):6774-80 [18454528.001]
  • (PMID = 20698561.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095298-07S1; United States / NCI NIH HHS / CA / R01 CA095298; United States / NCI NIH HHS / CA / 3R01 CA095298-07S1; United States / NCI NIH HHS / CA / R01 CA095298-07S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1,4-benzenedicarboxylate; 0 / Amines; 0 / Anhydrides; 0 / Organometallic Compounds; 0 / Phthalic Acids; CPD4NFA903 / Aluminum; OP0UW79H66 / Methane
  • [Other-IDs] NLM/ NIHMS228112; NLM/ PMC2939856
  •  go-up   go-down






Advertisement